Device for influencing blood flow of blood vessel and method thereof

By designing an implantable ultrasound device, using ultrasound energy to induce the release of NO and ATP in the vascular endothelium, the problem of insufficient penetration depth and durability of the device in the prior art is solved, and effective treatment of peripheral artery disease and pulmonary hypertension is achieved. .

CN118900710APending Publication Date: 2024-11-05NOVA PLUS LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202280088068.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2022-11-29
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing wearable ultrasonic devices are limited in terms of penetration depth and durability, and have a low acceptance rate for patients, making them difficult to use for a long time, and cannot effectively improve the release of nitric oxide (NO) and adenosine triphosphate (ATP) in the vascular endothelium. This leads to poor efficacy in treating diseases such as peripheral artery disease and pulmonary hypertension.

Method used

An implantable ultrasound device is designed, which includes an ultrasound transducer and a sensor that automatically activates or is controlled by monitoring the physiological state of the patient, and applies ultrasound energy to specific blood vessels or tissues to induce the release of NO and ATP, using Piezoelectric transducers and on-skin remote controls enable precise energy application and parameter adjustment.

Benefits of technology

It improves the release of NO and ATP in the vascular endothelium, enhances local blood flow, improves the therapeutic effect of peripheral arterial disease and pulmonary hypertension, and the implantable design of the device improves durability and patient acceptance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900710A_ABST
    Figure CN118900710A_ABST
Patent Text Reader

Abstract

The present disclosure relates to an implantable device for delivering therapeutic energy to a patient. More specifically, it relates to an implantable ultrasound device adapted to affect vascular endothelium to induce release of at least one substance selected from nitric oxide NO and / or adenosine triphosphate (ATP). Furthermore, the present disclosure relates to the treatment of various medical conditions, such as pulmonary hypertension, peripheral arterial disease (PAD) and asthma, by enhancing local perfusion of specific target organs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to an implantable device for delivering therapeutic energy to a patient. More specifically, it relates to an implantable ultrasound device adapted to affect the vascular endothelium to induce the release of at least one substance selected from nitric oxide (NO) and / or adenosine triphosphate (ATP). In addition, the present disclosure generally relates to treating various medical conditions, such as pulmonary hypertension, peripheral arterial disease (PAD), and asthma, by enhancing local perfusion to specific target organs. Background Art

[0002] Nitric oxide (NO) is a reactive inorganic free radical gas and a molecule that promotes important physiological and pathological processes. Its emergence is one of the important biological discoveries in recent years.

[0003] This molecule is produced by cells that mediate important biological functions under a variety of physiological and pathological conditions. Examples include endothelial cells in the inner wall of blood vessels; Nitric oxide derived from these cells can relax smooth muscle and regulate blood pressure, and has a significant effect on the function of circulating blood cells (such as platelets and neutrophils) and on the smooth muscle of both blood vessels and other organs (such as airways). In the brain and elsewhere, nitric oxide acts as a neurotransmitter for non-adrenergic non-cholinergic neurons. In these cases, in response to various endogenous molecular signals, nitric oxide seems to be produced intermittently in small amounts. In the immune system, nitric oxide can be synthesized in large quantities with persistence. Its production is induced by exogenous or endogenous inflammatory stimulation, especially endotoxins and cytokines produced by host defense system cells in response to infectious and inflammatory stimulation. This induced production causes prolonged nitric oxide release, which contributes to host defense processes (such as killing bacteria and viruses) and pathologies associated with acute and chronic inflammation in a variety of diseases (Furchgott and Zawadzki 1980; Palmer et al. 1987).

[0004] In the field of vascular function, it has been reported that when the endothelium is exposed to shear stress caused by blood flow and changes in blood flow, NO production from endothelial cells and ATP release (Matthew A. Muller et al., Augmentation of Tissue Perfusion with Contrast Ultrasound: Influence of Three-Dimensional Beam Geometry and Conducted Vasodilation, Journal of the American Society of Echocardiography, doi: 10.1016 / j.echo.2021.02.018) will be physiologically stimulated (Taso et al. 1995; Uematsu et al. 1995; Ayajiki et al. 1996; Corson et al. 1996; Fleming et al. 1998). There are two possible mechanisms for endothelial cell NO production in response to fluid shear stress. Previous studies (Ando et al. 1988; Geiger et al. 1992; James et al. 1995) have determined that exposure of the endothelium to increased fluid shear stress can stimulate intracellular Ca storage. 2+ release, leading to the release of intracellular free Ca 2+ Concentrations increase, which increases the enzymatic activity of endothelial NO synthase (eNOS) to generate NO.

[0005] Recently, however, several studies (Ayajiki et al. 1996; Corson et al. 1996; Fleming et al. 1998) reported that eNOS is activated by Ca2+ in response to fluid shear stress. 2+ They proposed that tyrosine phosphorylation and intracellular pH (Ayajiki et al. 1996), phosphorylation of eNOS (Corson et al. 1996) and tyrosine kinase inhibitor-sensitive pathways (Fleming et al. 1998) play an important role in NO production.

[0006] In addition to this physiological stimulation, recent reports indicate that ultrasound application can mimic the shear forces required to induce vasodilation, increased blood flow, and pH changes in terms of NO generation from blood vessels in a frequency- and amplitude-dependent manner (Mason et al., Augmentation of Tissue Perfusion in Patients With Peripheral Artery Disease Using Microbubble Cavitation, JACC Cardiovasc Imaging 2020 Mar;13(3):641-651; Belcik et al., Augmentation of limb perfusion and reversal of tissue ischemia produced by ultrasound-mediated microbubble cavitation, Circ. Cardiovasc Imaging. 2015 Apr;8(4):e002979; Kiyoshi Iida et al. Noninvasive low-frequency ultrasound energy causes vasodilation in humans; J Am Coll Cardiol. 2006 Aug 1;48(3):532-7; Muller et al., Treatment of Limb Ischemia withConducted Effects of Catheter-Based Endovascular Ultrasound, Ultrasound MedBiol. 2021 Aug;47(8):2277-2285;).

[0007] One of the most notable potential uses of NO induction and ATP release is in the treatment of ischemic tissue in peripheral arterial disease (PAD). PAD is the narrowing or blockage of arteries due to atherosclerosis (the buildup of fatty plaques), with or without calcification.

[0008] Stenosis or PAD can occur in any blood vessel, but is more common in the legs or lower extremities. PAD is a chronic disease. In moderate forms, it manifests as claudication. In severe forms, PAD manifests as critical limb ischemia (CLI). CLI is a severe blockage of an artery in a lower extremity that significantly reduces blood flow. Peripheral artery disease (PAD) and ischemic tissue are the most common forms of atherosclerosis, affecting many people worldwide. As a result of this disease, patients are limited in their mobility (claudication) and their quality of life is severely affected. This disease may progress to more severe stages and eventually present a risk of amputation, requiring revascularization treatments (such as arterial bypass surgery, stenting or angioplasty, opening the artery in the catheterization laboratory and placing a stent), but in the early stages, many people experience pain during physical activity (such as walking); in severe cases, patients experience pain in the feet or toes even when they are at rest. Complications of poor blood circulation can include ulcers and wounds in the legs and feet that do not heal. If left untreated, CLI complications may lead to amputation of the affected limb. Such conditions can be treated medically with exercise and medications such as cilostazol, which modestly improves walking ability by inhibiting platelet aggregation. However, in many cases, patients do not follow the prescribed exercise regimen due to pain associated with the disease.

[0009] Medical interventions such as balloon angioplasty, stenting, and surgery are options for treating patients with peripheral artery disease and critical limb ischemia. However, many of these procedures can fail. The consequences of graft failure include persistent ischemia, poor wound healing, gangrene, or amputation of the patient's limb.

[0010] The vasodilatory effects of nitric oxide (NO) and adenosine triphosphate (ATP), their positive effects on perfusion and release of NO from the endothelium (lining) of blood vessels are the main natural mechanisms for controlling local and systemic blood pressure. It is also known that external NO administration can cause local vasodilation, but the therapeutic use of systemic NO is limited because of its short half-life (less than 1 second) and the potential harmful effects that high doses can have on systemic blood pressure.

[0011] Another use of NO and ATP induction is for primary pulmonary hypertension. Pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) is elevated blood pressure in the pulmonary arteries and / or capillaries (collectively referred to as the pulmonary vasculature).

[0012] PH is a multifactorial disease phenomenon with a high mortality rate. The disease causes an increased workload on the right side of the heart and eventually leads to hypertrophy and dysfunction of both sides of the heart. Despite improvements in treatment, the prognosis of PH is poor, with a median survival of approximately 5 years.

[0013] Typically, patients with PH are treated with medications that are extremely expensive and not completely effective. Furthermore, treatment outcomes vary widely among patients with PH, primarily due to differences in underlying factors.

[0014] Thus, the present invention also relates to improving NO release in ischemic tissue (e.g., treating ischemic limbs or tissues affected by peripheral arterial disease) by applying ultrasound to the tissue under conditions effective to increase blood flow to the ischemic tissue. In other words, since nitric oxide has been shown to be a potent vasodilator with great therapeutic potential, there remains a long-standing need to locally increase the availability of nitric oxide at the target tissue (by utilizing ultrasound energy) to treat the tissues disclosed above.

[0015] Furthermore, it has been found that the application of ultrasound energy to increase NO and ATP release via implantable and / or wearable devices requires a large amount of energy to be focused on the blood vessels; furthermore, continued application of such energy may result in reduced efficacy due to physiological adaptation or other mechanisms. Therefore, in order to maintain high efficacy, it is advantageous to minimize the application period consistent with natural physiological needs and limit the duration of such stimulation to an optimal level (after which the marginal increase in NO production and vasodilation is reduced).

[0016] Several devices are known in the art. One of them is described in PCT Publication No. WO2018071908 of VIBRATO MEDICAL INC, which discloses a wearable, non-invasive ultrasound mode for treating a variety of medical conditions, including but not limited to peripheral vascular disease. The mode can be therapeutic ultrasound (TUS), and is configured to promote angiogenesis in the patient's body via mechanisms such as stimulating cavitation and shear stress. However, the device is wearable and its effect is limited (in terms of penetration depth). It should also be noted that such devices are bulky devices (suitable for wearable) and require acoustic gel between the transducer and the skin surface. Therefore, the patient's acceptance rate is low, and therefore (low acceptance rate and gel requirements) it is not suitable for long-term use.

[0017] Therefore, one object of the present invention is to use sensors embedded in an implantable device, external to the body (e.g., wearable sensors) and / or sensors implantable elsewhere in the body to detect periods when the patient's physiology creates an increased need for oxygenated blood and enhanced perfusion, and then apply energy (e.g., ultrasound) during that time to begin stimulating NO and ATP production. It is also an object of the present invention to test for optimal periods of NO and ATP production and limit the stimulation time to those periods. Summary of the invention

[0018] The long-standing need disclosed above can be solved by providing at least one implantable device for delivering therapeutic energy to a patient. More specifically, it relates to an implantable ultrasound device suitable for influencing the vascular endothelium to induce the release of nitric oxide (NO) and ATP, having the features of the independent claims. Further features of advantageous embodiments of the present disclosure are the subject of the dependent claims.

[0019] An object of the present invention is to provide a device suitable for implantation in the vicinity of at least one blood vessel or tissue containing flowing blood, the device comprising at least one ultrasonic transducer configured to provide ultrasonic energy to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is suitable for causing a physiological effect in the at least one blood vessel or tissue when applied; the device communicates with at least one on-skin remote control located outside the patient's body, the at least one on-skin remote control being suitable for controlling the ultrasonic energy;

[0020] Wherein the device is in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

[0021] It is another object of the present invention to provide the device as defined above, wherein said device is automatically activated when said at least one physiological state changes.

[0022] It is another object of the present invention to provide the device as defined above, wherein said patient activates said ultrasound energy or modifies said at least one treatment parameter when said at least one physiological state changes.

[0023] It is another object of the present invention to provide a device as defined above, suitable for treating patients with pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

[0024] It is another object of the present invention to provide the device as defined above, wherein the sensor is selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, echocardiogram, ultrasonic echo, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, acoustic blood pulse wave sensor, electrocardiogram sensor, ultrasound sensor or vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein the sensor is suitable for sensing at least one parameter selected from the group consisting of: movement of the patient, impedance, PPG signal, pH, acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

[0025] It is another object of the present invention to provide the device as defined above, wherein said ultrasound transducer is a transducer array.

[0026] It is another object of the present invention to provide the device as defined above, wherein the position and orientation of each of said transducers is controllable.

[0027] It is another object of the present invention to provide the device as defined above, wherein said ultrasound transducer array facilitates directing a focused ultrasound beam to said at least one blood vessel or tissue containing flowing blood.

[0028] It is another object of the present invention to provide the device as defined above, wherein said ultrasound transducer array facilitates beam steering of said ultrasound energy.

[0029] It is another object of the present invention to provide the device as defined above, wherein said ultrasound transducer array facilitates aiming of ultrasound energy on said at least one vessel or tissue containing flowing blood.

[0030] It is another object of the present invention to provide the device as defined above, wherein said array generates said ultrasonic energy at at least one ultrasonic carrier frequency.

[0031] Another object of the present invention is to provide a device as defined above, wherein at least one selected from the group consisting of said at least one on-skin remote control, said device, and any combination thereof comprises at least one coil for forming an inductive link and transmitting said ultrasonic energy from said at least one on-skin remote control transcutaneously to said at least one ultrasonic transducer.

[0032] It is another object of the present invention to provide the device as defined above, wherein said at least one on-skin remote control is adapted to drive said device by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

[0033] Another object of the present invention is to provide a device as defined above, wherein said at least one on-skin remote control is suitable for collecting data from said at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring said data; (b) adjusting the treatment provided to said patient; (c) maintaining the treatment provided to said patient unchanged; and any combination thereof.

[0034] It is another object of the present invention to provide the device as defined above, wherein said data is the shape of the pulse wave signal.

[0035] It is another object of the present invention to provide the device as defined above, wherein the data is a time delay between an ECG signal and a pulse wave signal.

[0036] It is another object of the present invention to provide a device as defined above, wherein the device is encapsulated in at least one layer of polyetheretherketone (PEEK), wherein the radiating surface of the PEEK is an acoustic matching layer; further, wherein the radiating surface of the PEEK has a quarter of λ, wherein λ is the wavelength of ultrasonic energy in PEEK.

[0037] It is another object of the present invention to provide the device as defined above, wherein said implant envelope is coated with parylene.

[0038] Another object of the present invention is to provide a device as defined above, wherein at least one of the transducers is a piezoelectric transducer made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-lead titanate, hard PZT, a composite material, PZT with non-uniform polarization, PZT with uniform polarization, and any combination thereof.

[0039] It is another object of the present invention to provide the device as defined above, wherein said ultrasonic energy is provided in a continuous manner or alternatively in pulses.

[0040] It is another object of the present invention to provide the device as defined above, wherein said at least one on-skin remote control is adapted to measure heart rate from said at least two pulse wave pulses.

[0041] It is another object of the present invention to provide the device as defined above, wherein analysis of said at least two pulse wave characteristics facilitates alignment of said implant relative to said at least one vessel or tissue containing flowing blood.

[0042] Another object of the present invention is to provide a device as defined above, wherein at least one of the following is true: (a) the ultrasonic frequency is between 10 kHz and 10 MHz; (b) the ultrasonic energy has a peak negative pressure between about 0.1 MPa and about 2 MPa; and any combination thereof.

[0043] It is another object of the present invention to provide the device as defined above, wherein the ultrasound energy is synchronized with the pulse wave signal

[0044] Another object of the present invention is to provide a device as defined above, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, the application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

[0045] It is another object of the present invention to provide the device as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0046] It is another object of the present invention to provide a device as defined above, wherein the physiological effect is selected from the group consisting of: vasodilation, increase in local ATP, enhanced ATP release, increase in local nitric oxide, enhanced nitric oxide release from the vascular endothelium; prolonged local nitric oxide effect; enhanced nitric oxide release from red blood cells; change in red blood cell function; change in oxygen release from hemoglobin, increased blood temperature; vasodilation; prolonged local nitric oxide effect; change in red blood cell function; change in oxygen release from hemoglobin; change in blood pH; modulation of the immune response of blood leukocytes; modulation of coagulation and / or platelet function; change in the function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis sessions, arterial dilation, increased blood perfusion, and combinations thereof.

[0047] Another object of the present invention is to provide a device as defined above, wherein at least one of the at least one on-skin remote controls is wearable by the patient; further, wherein the at least one on-skin remote control wearable by the patient is selected from the group consisting of: integrated in wearable socks, shoes, gloves, clothes, hats, and any combination thereof.

[0048] It is another object of the present invention to provide the device as defined above, wherein said ischemic tissue is selected from the group consisting of upper and lower limbs, arms, legs, and any combination thereof.

[0049] It is another object of the present invention to provide the device as defined above, wherein said at least one on-skin remote control is suitable for controlling at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0050] It is another object of the present invention to provide the device as defined above, wherein said at least one on-skin remote control is in communication with said at least one sensor.

[0051] Another object of the present invention is to provide a device as defined above, wherein when at least one of the physiological states of the patient changes, at least one of the following is performed: (a) activating the device and delivering ultrasonic energy to the at least one vessel or tissue so as to provide on-demand treatment; (b) modifying at least one treatment parameter of the ultrasonic energy to the at least one vessel or tissue so as to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

[0052] Another object of the present invention is to provide a device as defined above, wherein the sensor is selected from the group consisting of: a sensor implanted in the patient's body integrated within the device, a sensor worn by the patient, a remote sensor outside the patient's body integrated within at least one on-skin remote control, and any combination thereof.

[0053] It is another object of the present invention to provide the device as defined above, wherein said at least one ultrasound transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by said at least one blood vessel or tissue containing flowing blood.

[0054] It is another object of the present invention to provide the device as defined above, wherein said device is implanted subcutaneously.

[0055] Another object of the present invention is to provide a device suitable for implantation near at least one blood vessel or tissue containing flowing blood, the device comprising at least one pulse wave sensor suitable for sensing at least one sound wave generated by the at least one blood vessel or tissue containing flowing blood, and thereby monitoring at least one physiological state of the patient.

[0056] Another object of the present invention is to provide a device as defined above, wherein the at least one pulse wave sensor is at least one transducer; further, wherein the transducer is selected from the group consisting of: a capacitive element, an accelerometer, a piezoelectric element, an electromagnetic acoustic element, an electrostatic element, and any combination thereof.

[0057] It is another object of the present invention to provide a device as defined above, wherein said device communicates or otherwise comprises at least one sensor selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, an echocardiogram, an ultrasonic echo, a hydrophone, a thermometer, a core body temperature, a heart pulse rate, a pulse wave characteristic, a glucose sensor, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, an electrocardiogram sensor, an ultrasound sensor or a vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein said sensor is suitable for sensing at least one parameter selected from the group consisting of: movement of the patient, impedance, a PPG signal, pH, an acoustic signal, pressure, temperature, heart rate, pulse wave characteristic, glucose level, blood pressure, and any combination thereof.

[0058] It is another object of the present invention to provide the device as defined above, wherein said ultrasound transducer is a transducer array.

[0059] It is another object of the present invention to provide the device as defined above, wherein the device is encapsulated in at least one layer of polyetheretherketone (PEEK), wherein the radiating surface of the PEEK is the acoustic matching layer.

[0060] It is another object of the present invention to provide the device as defined above, wherein said implant envelope is coated with parylene.

[0061] Another object of the present invention is to provide a device as defined above, wherein at least one of the transducers is a piezoelectric transducer made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-lead titanate, hard PZT, a composite material, PZT with non-uniform polarization, PZT with uniform polarization, and any combination thereof.

[0062] Another object of the present invention is to provide a device as defined above, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, the application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

[0063] It is another object of the present invention to provide the device as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0064] It is another object of the present invention to provide the device as defined above, wherein said device is implanted subcutaneously.

[0065] Another object of the present invention is to provide an implant near or within at least one blood vessel or tissue containing flowing blood, the implant comprising:

[0066] i. at least one housing comprising at least one coil for forming an inductive link and transmitting said ultrasonic energy transcutaneously from at least one on-skin remote control to at least one ultrasonic transducer;

[0067] ii. at least one sealed pigtail connected by wire or wirelessly to said at least one housing comprising said at least one ultrasonic transducer, the at least one ultrasonic transducer being configured to couple ultrasonic energy to said at least one blood vessel or tissue containing flowing blood, wherein said ultrasonic energy is suitable for causing a physiological effect in said at least one blood vessel or tissue when applied;

[0068] The housing is in communication with the at least one on-skin remote control located external to the patient, the at least one on-skin remote control being adapted to control the ultrasound energy.

[0069] It is another object of the present invention to provide the implant as defined above, wherein at least one selected from the group consisting of said at least one housing, said at least one sealing pigtail and any combination thereof communicates with at least one sensor adapted to monitor at least one physiological state of a patient.

[0070] It is another object of the present invention to provide the implant as defined above, wherein said implant is automatically activated when said at least one physiological state changes.

[0071] It is another object of the present invention to provide the implant as defined above, wherein said patient activates said ultrasound energy or modifies said at least one treatment parameter when said at least one physiological state changes.

[0072] It is another object of the present invention to provide an implant as defined above suitable for treating pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma patients, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

[0073] It is another object of the present invention to provide an implant as defined above, wherein the sensor is selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, an echocardiogram, an ultrasonic echo, a hydrophone, a thermometer, a core body temperature, a heart pulse rate, a pulse wave characteristic, a glucose sensor, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, an acoustic blood pulse wave sensor, an electrocardiogram sensor, an ultrasound sensor or a vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein the sensor is suitable for sensing at least one parameter selected from the group consisting of: movement of the patient, impedance, a PPG signal, pH, an acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

[0074] It is another object of the present invention to provide the implant as defined above, wherein said ultrasound transducer is a transducer array.

[0075] It is another object of the present invention to provide the implant as defined above, wherein said array generates said ultrasonic energy at at least one ultrasonic carrier frequency.

[0076] It is another object of the present invention to provide an implant as defined above, wherein said at least one on-skin remote control comprises at least one coil for forming an inductive link and transmitting said ultrasonic energy from said at least one on-skin remote control transcutaneously to said at least one ultrasonic transducer.

[0077] It is another object of the present invention to provide the implant as defined above, wherein said at least one on-skin remote control is adapted to drive said implant by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

[0078] Another object of the present invention is to provide an implant as defined above, wherein said at least one on-skin remote control is suitable for collecting data from said at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring said data; (b) adjusting the treatment provided to said patient; (c) maintaining the treatment provided to said patient unchanged; and any combination thereof.

[0079] It is another object of the present invention to provide the implant as defined above, wherein said data is the shape of the pulse wave signal.

[0080] It is another object of the present invention to provide the implant as defined above, wherein said data is a time delay between an ECG signal and a pulse wave signal.

[0081] It is another object of the present invention to provide the implant as defined above, wherein said implant is implanted subcutaneously.

[0082] It is another object of the present invention to provide the implant as defined above, wherein said implant envelope is coated with parylene.

[0083] Another object of the present invention is to provide an implant as defined above, wherein at least one of the transducers is a piezoelectric transducer made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-lead titanate, hard PZT, a composite material, PZT with inhomogeneous polarization, PZT with uniform polarization, and any combination thereof.

[0084] It is another object of the present invention to provide the implant as defined above, wherein said ultrasonic energy is provided in a continuous manner or alternatively in pulses.

[0085] It is another object of the present invention to provide the implant as defined above, wherein said at least one on-skin remote control is adapted to measure heart rate from said at least two pulse wave pulses.

[0086] It is another object of the present invention to provide the implant as defined above, wherein analysis of said at least two pulse wave characteristics facilitates alignment of said implant relative to the position of said at least one vessel or tissue containing flowing blood.

[0087] Another object of the present invention is to provide an implant as defined above, wherein at least one of the following is true: (a) the ultrasonic frequency is between 10 kHz and 10 MHz; (b) the ultrasonic energy has a peak negative pressure between about 0.1 MPa and about 2 MPa; and any combination thereof.

[0088] It is another object of the present invention to provide the implant as defined above, wherein said ultrasound energy is synchronized with the pulse wave signal.

[0089] Another object of the present invention is to provide an implant as defined above, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in the NO level in at least one of the vessels or tissues, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, the application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

[0090] It is another object of the present invention to provide the implant as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0091] It is another object of the present invention to provide the implant as defined above, wherein the physiological effect is selected from the group consisting of: vasodilation, increase in local ATP, enhanced ATP release, increase in local nitric oxide, enhanced nitric oxide release from the vascular endothelium; prolonged local nitric oxide effect; enhanced nitric oxide release from red blood cells; alteration of red blood cell function; alteration of oxygen release from hemoglobin, increased blood temperature; vasodilation; prolonged local nitric oxide effect; alteration of red blood cell function; alteration of oxygen release from hemoglobin; alteration of blood pH; modulation of the immune response of blood leukocytes; modulation of coagulation and / or platelet function; alteration of the function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis sessions, arterial dilation, increased blood perfusion, and combinations thereof.

[0092] Another object of the present invention is to provide an implant as defined above, wherein at least one of the at least one on-skin remote controls is wearable by the patient; further, wherein the at least one on-skin remote control wearable by the patient is selected from the group consisting of: integrated in wearable socks, shoes, gloves, clothes, hats, and any combination thereof.

[0093] It is another object of the present invention to provide the implant as defined above, wherein said ischemic tissue is selected from the group consisting of upper and lower limbs, arms, legs, and any combination thereof.

[0094] It is another object of the present invention to provide an implant as defined above, wherein said at least one on-skin remote control is suitable for controlling at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0095] It is another object of the present invention to provide the implant as defined above, wherein said at least one on-skin remote control is in communication with said at least one sensor.

[0096] Another object of the present invention is to provide an implant as defined above, wherein when at least one of the physiological states of the patient changes, at least one of the following is performed: (a) delivering the ultrasonic energy to the at least one blood vessel or tissue so as to provide on-demand treatment; (b) modifying at least one treatment parameter provided by the ultrasonic energy to the at least one blood vessel or tissue so as to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

[0097] Another object of the present invention is to provide an implant as defined above, wherein the sensor is selected from the group consisting of: a sensor integrated in the at least one shell, a sensor implanted in the patient's body integrated in the at least one pigtail, a sensor worn by the patient, a remote sensor outside the patient's body integrated in the at least one on-skin remote control, and any combination thereof.

[0098] It is another object of the present invention to provide the implant as defined above, wherein said at least one ultrasound transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by said at least one blood vessel or tissue containing flowing blood.

[0099] It is another object of the present invention to provide the implant as defined above, wherein said at least one ultrasound transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by said at least one blood vessel or tissue containing flowing blood.

[0100] Another object of the present invention is to provide a method for treating a patient, the method comprising the following steps:

[0101] a. providing at least one device adapted to be implanted in a patient's body near at least one blood vessel or tissue containing flowing blood, the at least one device comprising at least one ultrasonic transducer configured to provide ultrasonic energy to be applied to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is adapted to induce a physiological effect in the at least one blood vessel or tissue when applied;

[0102] b. communicating said device with at least one on-skin remote controller located outside the patient's body, said at least one on-skin remote controller being adapted to control said means for applying said ultrasonic energy;

[0103] c. implanting the at least one device near at least one blood vessel or tissue containing flowing blood;

[0104] d. Placing the device in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

[0105] Another object of the present invention is to provide a method for treating a patient, the method comprising the following steps:

[0106] a. providing at least one implant near or within at least one blood vessel or tissue containing flowing blood, the at least one implant comprising (i) at least one housing comprising at least one coil for forming an inductive link and transcutaneously transmitting the ultrasonic energy from at least one on-skin remote control to at least one ultrasonic transducer; (ii) at least one sealed pigtail connected by wire or wireless connection to the at least one housing comprising the at least one ultrasonic transducer, the at least one ultrasonic transducer being configured to couple ultrasonic energy to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is suitable for causing a physiological effect in the at least one blood vessel or tissue when applied;

[0107] b. communicating said implant with at least one on-skin remote controller located outside the patient's body, said at least one on-skin remote controller being adapted to control said device for applying said ultrasonic energy;

[0108] c. implanting the at least one implant near or within at least one blood vessel or tissue containing flowing blood;

[0109] d. Placing the implant in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

[0110] Another object of the present invention is to provide a method for monitoring at least one physiological state of a patient, the method comprising the following steps:

[0111] a. providing at least one implant near at least one blood vessel or tissue containing flowing blood, the at least one implant comprising at least one pulse wave sensor adapted to sense at least one acoustic wave generated by the at least one blood vessel or tissue containing flowing blood, and thereby monitoring the at least one physiological state of the patient;

[0112] b. implanting the at least one implant near at least one blood vessel or tissue containing flowing blood;

[0113] c. sensing at least one acoustic wave generated by the at least one blood vessel or tissue containing flowing blood to thereby monitor at least one physiological state of the patient.

[0114] It is an object of the present invention to provide a device adapted for implantation in a patient adjacent, near or within at least one blood vessel or tissue containing flowing blood, the device comprising means (e.g., a transducer) for applying ultrasonic energy to at least one blood vessel or tissue containing flowing blood, wherein said means for applying ultrasonic energy is adapted to induce a physiological effect in said at least one blood vessel or tissue when applied;

[0115] The device is in communication with at least one sensor adapted to monitor at least one physiological state of the patient such that, when the physiological state changes, at least one of the following is performed: (a) delivering the ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (b) modifying at least one treatment parameter provided by the ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

[0116] It is another object of the present invention to provide the device as defined above, wherein said device is automatically activated when said at least one physiological state changes.

[0117] It is another object of the present invention to provide the device as defined above, wherein said patient activates said ultrasound energy or modifies said at least one treatment parameter when said at least one physiological state changes.

[0118] It is another object of the present invention to provide the device as defined above, wherein the sensor is selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, echocardiogram, ultrasonic echo, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0119] It is another object of the present invention to provide the device as defined above, wherein the sensor is suitable for sensing at least one parameter selected from the group consisting of: movement of the patient, impedance, PPG signal, pH, acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

[0120] It is another object of the present invention to provide the device as defined above, wherein said device is in communication with at least one remote control located outside the patient's body, the at least one remote control being adapted to control said means for applying said ultrasonic energy.

[0121] Another object of the present invention is to provide a device as defined above, wherein the sensor is selected from the group consisting of: a sensor implanted in the patient's body integrated within the device, a sensor worn by the patient, a remote sensor outside the patient's body integrated within the at least one controller, and any combination thereof.

[0122] Another object of the present invention is to provide a device as defined above, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, the application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

[0123] It is another object of the present invention to provide the device as defined above, wherein at least one treatment parameter is selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0124] It is another object of the present invention to provide the device as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0125] It is another object of the present invention to provide the device as defined above, wherein said device is in communication with at least one battery; said at least one battery being implanted or located outside the patient's body.

[0126] It is another object of the present invention to provide the device as defined above, wherein said at least one battery is adapted to be wirelessly charged.

[0127] It is another object of the present invention to provide the device as defined above, wherein the physiological effect is selected from the group consisting of: vasodilation; increase in local nitric oxide; enhancement of nitric oxide release from the vascular endothelium; prolonged local nitric oxide effect; alteration of erythrocyte function; alteration of oxygen release from hemoglobin, increase in blood temperature; vasodilation; prolonged local nitric oxide effect; alteration of erythrocyte function; alteration of oxygen release from hemoglobin; alteration of blood pH; modulation of immune response of blood leukocytes; modulation of coagulation and / or platelet function; alteration of the function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis sessions, arterial dilation, increased blood perfusion, and combinations thereof

[0128] It is another object of the present invention to provide the device as defined above, wherein the ultrasonic energy is provided at a frequency range of about 20 kHz to about 10 MHz.

[0129] It is another object of the present invention to provide the device as defined above, wherein the ultrasonic energy is provided by at least one selected from the group consisting of: at least one piezoelectric transducer generating ultrasonic energy, at least one passive ferromagnetic element, at least one capacitive micromachined ultrasonic transducer, a CMUT, a concave transducer, a convex transducer, and any combination thereof.

[0130] It is another object of the present invention to provide the device as defined above, wherein the piezoelectric transducer is made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, composite materials, and any combination thereof.

[0131] It is another object of the present invention to provide the device as defined above, wherein the piezoelectric transducer is shielded by Gaussian apodization.

[0132] It is another object of the present invention to provide the device as defined above, wherein said Gaussian apodization is provided by material polarization.

[0133] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers is adapted to charge said device.

[0134] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers is adapted to charge said device by at least one method selected from the group consisting of: electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

[0135] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers comprises at least one coil.

[0136] It is another object of the present invention to provide a device as defined above, wherein said at least one sensor is adapted to sense at least one pulse wave characteristic reflected from said device by at least one method selected from the group consisting of: (a) passive acoustic sensing of at least one signal reflected from said at least one blood vessel or tissue; (b) active transmission of at least one acoustic signal; (c) echo; and any combination thereof.

[0137] It is another object of the present invention to provide the device as defined above, wherein the device is adapted to sense heart rate from said at least one pulse wave characteristic.

[0138] It is another object of the present invention to provide the device as defined above, wherein analysis of said at least one pulse wave characteristic facilitates alignment of said device relative to the position of said at least one vessel or tissue containing flowing blood.

[0139] It is another object of the present invention to provide the device as defined above, wherein said alignment is indicated to the patient or his caregiver.

[0140] It is another object of the present invention to provide the device as defined above, wherein said alignment is indicated by at least one indication means selected from the group consisting of audio means, visual means, tactile means and any combination thereof.

[0141] It is another object of the present invention to provide the device as defined above, wherein analysis of said at least one pulse wave characteristic is indicative of said cause of said physiological effect.

[0142] It is another object of the present invention to provide the device as defined above, wherein the ultrasonic energy is provided by an array of piezoelectric transducers, each of the piezoelectric transducers generating ultrasonic wave energy.

[0143] It is another object of the present invention to provide the device as defined above, wherein said piezoelectric transducer array is a phased array.

[0144] It is another object of the present invention to provide the device as defined above, wherein activating at least one of said transducers according to a predetermined scheme causes fine adjustment of the position of said implant relative to said at least one blood vessel so as to align said implant therewith.

[0145] It is another object of the present invention to provide the device as defined above, wherein said ultrasonic energy is provided in a continuous manner or alternatively in pulses.

[0146] Another object of the present invention is to provide a device as defined above, wherein at least one of the controllers is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) modifying at least one treatment parameter of the treatment regimen; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof.

[0147] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers is wearable by said patient.

[0148] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers wearable by said patient is selected from the group consisting of: integrated in a wearable sock, a shoe, a glove, a garment, a hat, and any combination thereof.

[0149] It is another object of the present invention to provide the device as defined above, wherein at least one of said controllers is integrated in the environment of said patient.

[0150] It is another object of the present invention to provide the device as defined above, wherein at least one of the controllers communicates with at least one selected from the group consisting of a CPU, a smartphone, and any combination thereof.

[0151] It is another object of the present invention to provide a device as defined above, suitable for treating patients with pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

[0152] It is another object of the present invention to provide the device as defined above, wherein said ischemic tissue is selected from the group consisting of upper and lower limbs, arms, legs, and any combination thereof.

[0153] It is another object of the present invention to provide a device as defined above, adapted to provide said ultrasound energy to increase blood flow.

[0154] It is another object of the present invention to provide the device as defined above, wherein said ultrasonic energy is provided at at least two substantially different frequencies of a carrier signal.

[0155] It is another object of the present invention to provide the device as defined above, wherein said device comprises at least one piezoelectric transducer adapted to generate said ultrasonic energy at one of said at least two substantially different frequencies of a carrier signal.

[0156] It is another object of the present invention to provide the device as defined above, wherein said device additionally comprises at least one electromagnetic acoustic transducer mechanically coupled to said at least one piezoelectric transducer, the at least one piezoelectric transducer being adapted to generate said ultrasonic energy at one of said at least substantially different frequencies of a carrier signal.

[0157] It is another object of the present invention to provide the device as defined above, wherein said at least one electromagnetic acoustic transducer is at least one ferromagnetic sheet.

[0158] It is another object of the present invention to provide the device as defined above, wherein a frequency of the carrier signal is selected from the range of about 20 kHz to about 10 MHz.

[0159] It is another object of the present invention to provide the device as defined above, wherein the second frequency of the carrier signal is in a range selected from about 20 kHz to about 10 MHz.

[0160] It is another object of the present invention to provide the device as defined above, wherein said device is encapsulated in at least one layer of polyetheretherketone (PEEK).

[0161] It is another object of the present invention to provide the device as defined above, wherein said device comprises at least one processor adapted to control at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0162] It is another object of the present invention to provide the device as defined above, wherein said at least one processor is in communication with said at least one sensor.

[0163] Another object of the present invention is to provide a device as defined above, wherein said at least one processor is suitable for collecting data from said at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring said data; (b) modifying the treatment provided to said patient; (c) maintaining the treatment provided to said patient unchanged; and any combination thereof.

[0164] Another object of the present invention is to provide a method for treating a patient, the method comprising the following steps:

[0165] a. providing at least one implantable device adapted to be implanted in a patient's body adjacent to, near or within at least one blood vessel or tissue containing flowing blood, the at least one implantable device comprising a means for applying ultrasonic energy to at least one blood vessel or tissue containing flowing blood, wherein the means for applying ultrasonic energy is adapted to induce a physiological effect in the at least one blood vessel or tissue when applied;

[0166] b. implanting said at least one device near or within at least one blood vessel or tissue containing flowing blood;

[0167] c. enabling the device to communicate with at least one sensor, the at least one sensor being suitable for monitoring at least one physiological state of the patient so that when it changes, at least one of the following is performed: (a) delivering the ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (b) modifying at least one treatment parameter provided by the ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (c) notifying the change; (d) any combination thereof; thereby treating the patient.

[0168] It is another object of the present invention to provide the method as defined above, wherein said device is automatically activated when said at least one physiological state changes.

[0169] It is another object of the present invention to provide the method as defined above, wherein said patient activates said ultrasound energy or modifies said at least one treatment parameter when said at least one physiological state changes.

[0170] It is another object of the present invention to provide the method as defined above, wherein the sensor is selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, an echocardiogram, an ultrasonic echo, a hydrophone, a thermometer, core body temperature, heart pulse rate, pulse wave characteristics, a glucose sensor, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0171] It is another object of the present invention to provide the method as defined above, wherein the sensor is adapted to sense at least one parameter selected from the group consisting of: movement of the patient, impedance, PPG signal, pH, acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

[0172] It is another object of the present invention to provide the method as defined above, wherein said apparatus is in communication with at least one remote controller located outside the patient's body, the at least one remote controller being adapted to control said means for applying said ultrasonic energy.

[0173] Another object of the present invention is to provide a method as defined above, wherein the sensor is selected from the group consisting of: a sensor implanted in the patient's body integrated in the device, a sensor worn by the patient, a remote sensor outside the patient's body integrated in the at least one controller, and any combination thereof.

[0174] Another object of the present invention is to provide a method as defined above, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, the application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

[0175] It is another object of the present invention to provide the method as defined above, wherein at least one treatment parameter is selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0176] It is another object of the present invention to provide the method as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0177] It is another object of the present invention to provide the method as defined above, wherein said device is in communication with at least one battery; said at least one battery being implanted or located outside the patient's body.

[0178] It is another object of the present invention to provide the method as defined above, wherein said at least one battery is adapted for wireless charging.

[0179] It is another object of the present invention to provide the method as defined above, wherein said physiological effect is selected from the group consisting of: vasodilation; increase in local nitric oxide; enhancement of nitric oxide release from vascular endothelium; prolongation of local nitric oxide effect; change in erythrocyte function; change in oxygen release from hemoglobin, increase in blood temperature; vasodilation; prolongation of local nitric oxide effect; change in erythrocyte function; change in oxygen release from hemoglobin; change in blood pH; modulation of immune response of blood leukocytes; modulation of coagulation and / or platelet function; change in function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis sessions, arterial dilation, increased blood perfusion, and combinations thereof

[0180] It is another object of the present invention to provide the method as defined above, wherein the ultrasonic energy is provided at a frequency range of about 20 kHz to about 10 MHz.

[0181] It is another object of the present invention to provide the method as defined above, wherein the ultrasonic energy is provided by at least one selected from the group consisting of: at least one piezoelectric transducer generating ultrasonic energy, at least one passive ferromagnetic element, at least one capacitive micromachined ultrasonic transducer, a CMUT, a concave transducer, a convex transducer, and any combination thereof.

[0182] It is another object of the present invention to provide the method as defined above, wherein the piezoelectric transducer is made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, composite materials, and any combination thereof.

[0183] It is another object of the present invention to provide the method as defined above, wherein the piezoelectric transducer is shielded by Gaussian apodization.

[0184] It is another object of the present invention to provide the method as defined above, wherein said Gaussian apodization is provided by material polarization.

[0185] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers is adapted to charge said device.

[0186] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers is adapted to charge said device by at least one method selected from the group consisting of: electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

[0187] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers comprises at least one coil.

[0188] It is another object of the present invention to provide a method as defined above, wherein said at least one sensor is adapted to sense at least one pulse wave characteristic reflected from said device by at least one method selected from the group consisting of: (a) passive acoustic sensing of at least one signal reflected from said at least one blood vessel or tissue; (b) active transmission of at least one acoustic signal; (c) echo; and any combination thereof.

[0189] It is another object of the present invention to provide the method as defined above, wherein the device is adapted to sense heart rate from said at least one pulse wave characteristic.

[0190] It is another object of the present invention to provide the method as defined above, wherein analysis of said at least one pulse wave characteristic facilitates alignment of said device relative to the position of said at least one vessel or tissue containing flowing blood.

[0191] It is another object of the present invention to provide the method as defined above, wherein said alignment is indicated to the patient or his caregiver.

[0192] It is another object of the present invention to provide the method as defined above, wherein said alignment is indicated by at least one indication means selected from the group consisting of audio means, visual means, tactile means and any combination thereof.

[0193] It is another object of the present invention to provide the method as defined above, wherein analysis of said at least one pulse wave characteristic is indicative of said cause of said physiological effect.

[0194] It is another object of the present invention to provide the method as defined above, wherein the ultrasonic energy is provided by an array of piezoelectric transducers, each of the piezoelectric transducers generating ultrasonic wave energy.

[0195] It is another object of the present invention to provide the method as defined above, wherein said piezoelectric transducer array is a phased array.

[0196] It is another object of the present invention to provide the method as defined above, wherein activating at least one of said transducers according to a predetermined scheme causes fine adjustment of the position of said implant relative to said at least one blood vessel in order to align said implant therewith.

[0197] It is another object of the present invention to provide the method as defined above, wherein said ultrasonic energy is provided in a continuous manner or alternatively in pulses.

[0198] Another object of the present invention is to provide a method as defined above, wherein at least one of the controllers is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) modifying at least one treatment parameter of the treatment regimen; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof.

[0199] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers is wearable by said patient.

[0200] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers wearable by said patient is selected from the group consisting of: integrated in a wearable sock, a shoe, a glove, a garment, a hat, and any combination thereof.

[0201] It is another object of the present invention to provide the method as defined above, wherein at least one of said controllers is integrated in an environment of said patient.

[0202] It is another object of the present invention to provide the method as defined above, wherein at least one of the controllers communicates with at least one selected from the group consisting of a CPU, a smartphone, and any combination thereof.

[0203] It is another object of the present invention to provide a method as defined above suitable for treating patients with pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

[0204] It is another object of the present invention to provide the method as defined above, wherein said ischemic tissue is selected from the group consisting of upper and lower limbs, arms, legs, and any combination thereof.

[0205] It is another object of the present invention to provide the method as defined above, adapted to provide said ultrasound energy so as to increase blood flow.

[0206] It is another object of the present invention to provide the method as defined above, wherein said ultrasonic energy is provided at at least two substantially different frequencies of a carrier signal.

[0207] It is another object of the present invention to provide the method as defined above, wherein said device comprises at least one piezoelectric transducer adapted to generate said ultrasonic energy at one of said at least two substantially different frequencies of a carrier signal.

[0208] It is another object of the present invention to provide the method as defined above, wherein said apparatus additionally comprises at least one electromagnetic acoustic transducer mechanically coupled to said at least one piezoelectric transducer, the at least one piezoelectric transducer being adapted to generate said ultrasonic energy at one of said at least substantially different frequencies of a carrier signal.

[0209] It is another object of the present invention to provide the method as defined above, wherein said at least one electromagnetic acoustic transducer is at least one ferromagnetic sheet.

[0210] It is another object of the present invention to provide the method as defined above, wherein a frequency of the carrier signal is selected from the range of about 20 kHz to about 10 MHz.

[0211] It is another object of the present invention to provide the method as defined above, wherein the second frequency of the carrier signal is within a range selected from about 20 kHz to about 10 MHz.

[0212] It is another object of the present invention to provide the method as defined above, wherein said device is encapsulated in at least one layer of polyetheretherketone (PEEK).

[0213] It is another object of the present invention to provide the method as defined above, wherein said device comprises at least one processor adapted to control at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0214] It is another object of the present invention to provide the method as defined above, wherein said at least one processor is in communication with said at least one sensor.

[0215] Another object of the present invention is to provide a method as defined above, wherein said at least one processor is suitable for collecting data from said at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring said data; (b) modifying the treatment provided to said patient; (c) maintaining the treatment provided to said patient unchanged; and any combination thereof.

[0216] It is another object of the present invention to provide the method as defined above, additionally comprising the step of orienting at least two devices at the same position relative to said at least one vessel or tissue containing flowing blood.

[0217] It is another object of the present invention to provide the method as defined above, additionally comprising the step of orienting at least two devices at substantially different positions relative to said at least one vessel or tissue containing flowing blood.

[0218] It is another object of the present invention to provide the method as defined above, additionally comprising the step of achieving focusing of said ultrasound energy on said at least one blood vessel or tissue by said positioning of said at least two devices.

[0219] It is another object of the present invention to provide the method as defined above, additionally comprising the step of enabling communication between at least two devices.

[0220] Another object of the present invention is to provide a system comprising a plurality of implantable ultrasound devices, at least one of which is to be implanted in a patient's body adjacent to, near or within at least one blood vessel or tissue containing flowing blood, the device comprising a means for applying ultrasonic energy to at least one blood vessel or tissue containing flowing blood, wherein the means for applying ultrasonic energy is adapted to induce a physiological effect in the at least one blood vessel or tissue when applied; wherein at least one of the devices communicates with at least one sensor, the at least one sensor being adapted to monitor at least one physiological state of the patient so that when it changes, at least one of the following is performed: (a) delivering the ultrasonic energy to the at least one blood vessel or tissue so as to provide on-demand treatment; (b) modifying at least one treatment parameter provided by the ultrasonic energy to the at least one blood vessel or tissue so as to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

[0221] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices is automatically activated when said at least one physiological state changes.

[0222] It is another object of the present invention to provide the system as defined above, wherein said patient activates said ultrasound energy or modifies said at least one treatment parameter when said at least one physiological state changes.

[0223] It is another object of the present invention to provide the system as defined above, wherein the sensor is selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, echocardiogram, ultrasonic echo, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0224] It is another object of the present invention to provide the system as defined above, wherein the sensor is adapted to sense at least one parameter selected from the group consisting of: movement of the patient, impedance, PPG signal, pH, acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure and any combination thereof.

[0225] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices is in communication with at least one remote controller located outside the patient's body, the at least one remote controller being adapted to control said means for applying said ultrasonic energy.

[0226] Another object of the present invention is to provide a system as defined above, wherein the sensor is selected from the group consisting of: a sensor implanted in the patient's body integrated in at least one of the devices, a sensor worn by the patient, a remote sensor outside the patient's body integrated in at least one controller, and any combination thereof.

[0227] Another object of the present invention is to provide a system as defined above, wherein said physiological state or change thereof is selected from the group consisting of: position of the patient, participation in physical activity, reduction of NO levels in said at least one vessel or tissue, tissue perfusion, initiation of physical activity, change of at least one parameter associated with said physical activity, position of the patient relative to the ground, change of said position of the patient relative to the ground, application of at least one medical treatment to said patient, change of application of at least one medical treatment to said patient, and any combination thereof.

[0228] It is another object of the present invention to provide the system as defined above, wherein at least one treatment parameter is selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0229] It is another object of the present invention to provide the system as defined above, wherein when said at least one physiological state changes, at least one notification is sent to said patient or any caregiver thereof.

[0230] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices is in communication with at least one battery; said at least one battery being implanted or located outside the patient's body.

[0231] It is another object of the present invention to provide the system as defined above, wherein said at least one battery is adapted to be wirelessly charged.

[0232] It is another object of the present invention to provide the system as defined above, wherein the physiological effect is selected from the group consisting of: vasodilation; increase in local nitric oxide; enhancement of nitric oxide release from the vascular endothelium; prolonged local nitric oxide effect; alteration of erythrocyte function; alteration of oxygen release from hemoglobin, increase in blood temperature; vasodilation; prolonged local nitric oxide effect; alteration of erythrocyte function; alteration of oxygen release from hemoglobin; alteration of blood pH; modulation of immune response of blood leukocytes; modulation of coagulation and / or platelet function; alteration of the function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis sessions, arterial dilation, increased blood perfusion, and combinations thereof

[0233] It is another object of the present invention to provide the system as defined above, wherein the ultrasonic energy is provided at a frequency range of about 20 kHz to about 10 MHz.

[0234] It is another object of the present invention to provide the system as defined above, wherein the ultrasonic energy is provided by at least one selected from the group consisting of: at least one piezoelectric transducer of an ultrasonic wave generating system, at least one passive ferromagnetic element, at least one capacitive micromachined ultrasonic transducer, a CMUT, a concave transducer, a convex transducer, and any combination thereof.

[0235] It is another object of the present invention to provide the system as defined above, wherein the piezoelectric transducer is made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, composite materials, and any combination thereof.

[0236] It is another object of the present invention to provide the system as defined above, wherein the piezoelectric transducer is shielded by Gaussian apodization.

[0237] It is another object of the present invention to provide the system as defined above, wherein said Gaussian apodization is provided by material polarization.

[0238] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers is adapted to charge at least one of said devices.

[0239] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers is adapted to charge at least one of said devices by at least one method selected from the group consisting of: electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

[0240] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers comprises at least one coil.

[0241] It is another object of the present invention to provide a system as defined above, wherein the at least one sensor is suitable for sensing at least one pulse wave characteristic of at least one of the reflections from the device by at least one method selected from the group consisting of: (a) acoustic sensing; (b) echo; and any combination thereof.

[0242] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices is adapted to sense heart rate from said at least one pulse wave characteristic.

[0243] It is another object of the present invention to provide the system as defined above, wherein analysis of said at least one pulse wave characteristic facilitates positional alignment of at least one of said devices relative to said at least one vessel or tissue containing flowing blood.

[0244] It is another object of the present invention to provide the system as defined above, wherein said alignment is indicated to the patient or his caregiver.

[0245] It is another object of the present invention to provide the system as defined above, wherein said alignment is indicated by at least one indication means selected from the group consisting of audio means, visual means, tactile means and any combination thereof.

[0246] It is another object of the present invention to provide the system as defined above, wherein analysis of said at least one pulse wave characteristic is indicative of said cause of said physiological effect.

[0247] It is another object of the present invention to provide the system as defined above, wherein the ultrasonic energy is provided by an array of piezoelectric transducers, each of the piezoelectric transducers generating ultrasonic wave energy.

[0248] It is another object of the present invention to provide the system as defined above, wherein said piezoelectric transducer array is a phased array.

[0249] It is another object of the present invention to provide the system as defined above, wherein activating at least one of said transducers according to a predetermined scheme causes fine adjustment of the position of said implant relative to said at least one blood vessel in order to align said implant therewith.

[0250] It is another object of the present invention to provide the system as defined above, wherein said ultrasonic energy is provided in a continuous manner or alternatively in pulses.

[0251] Another object of the present invention is to provide a system as defined above, wherein at least one of the controllers is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) modifying at least one treatment parameter of the treatment regimen; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof.

[0252] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers is wearable by said patient.

[0253] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers wearable by said patient is selected from the group consisting of: integrated in a wearable sock, a shoe, a glove, a garment, a hat, and any combination thereof.

[0254] It is another object of the present invention to provide the system as defined above, wherein at least one of said controllers is integrated in the environment of said patient.

[0255] It is another object of the present invention to provide the system as defined above, wherein at least one of the controllers communicates with at least one selected from the group consisting of a CPU, a smartphone, and any combination thereof.

[0256] It is another object of the present invention to provide a system as defined above, suitable for treating patients with pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

[0257] It is another object of the present invention to provide the system as defined above, wherein said ischemic tissue is selected from the group consisting of upper and lower limbs, arms, legs, and any combination thereof.

[0258] It is another object of the present invention to provide a system as defined above, adapted to provide said ultrasound energy to increase blood flow.

[0259] It is another object of the present invention to provide the system as defined above, wherein said ultrasonic energy is provided at at least two substantially different frequencies of a carrier signal.

[0260] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices comprises at least one piezoelectric transducer adapted to generate said ultrasonic energy at one of said at least two substantially different frequencies of a carrier signal.

[0261] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices additionally comprises at least one electromagnetic acoustic transducer mechanically coupled to said at least one piezoelectric transducer, the at least one piezoelectric transducer being adapted to generate said ultrasonic energy at one of said at least substantially different frequencies of a carrier signal.

[0262] It is another object of the present invention to provide the system as defined above, wherein said at least one electromagnetic acoustic transducer is at least one ferromagnetic sheet.

[0263] It is another object of the present invention to provide the system as defined above, wherein a frequency of the carrier signal is within a range selected from about 20 kHz to about 10 MHz.

[0264] It is another object of the present invention to provide the system as defined above, wherein the second frequency of the carrier signal is within a range selected from about 20 kHz to about 10 MHz.

[0265] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices is encapsulated in at least one layer of polyetheretherketone (PEEK).

[0266] It is another object of the present invention to provide the system as defined above, wherein at least one of said devices comprises at least one processor adapted to control at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of said ultrasonic energy.

[0267] It is another object of the present invention to provide the system as defined above, wherein said at least one processor is in communication with said at least one sensor.

[0268] Another object of the present invention is to provide a system as defined above, wherein said at least one processor is suitable for collecting data from said at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring said data; (b) modifying the treatment provided to said patient; (c) maintaining the treatment provided to said patient unchanged; and any combination thereof.

[0269] It is another object of the present invention to provide the system as defined above, wherein all of said plurality of implants are oriented at the same position relative to said at least one vessel or tissue containing flowing blood.

[0270] It is another object of the present invention to provide the system as defined above, wherein each of said plurality of implants is oriented relative to another of said plurality of implants at a substantially different position relative to said at least one blood vessel or tissue containing flowing blood.

[0271] It is a further object of the present invention to provide the system as defined above, wherein said positions of said plurality of implants are adapted to enable focusing of said energy on said at least one vessel or tissue containing flowing blood.

[0272] It is a final object of the present invention to provide the system as defined above, wherein at least two of said plurality of implantable devices communicate with each other.

[0273] Various other objectives, aspects and advantages of the present disclosure can be obtained through a study of the specification, drawings and appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0274] For simplicity and clarity of illustration, the elements shown in the figures are not necessarily drawn to scale. For example, the size of some elements may be exaggerated relative to other elements for the sake of clarity. In addition, reference numerals may be repeated in the drawings to indicate corresponding or similar elements.

[0275] The accompanying drawings are listed below.

[0276] Figures 1A to 1B A general overview of the system is shown, where the ultrasound transducer is located within the implant. The system includes various sensors, such as thermal sensors for protection, which can limit the temperature of the implant envelope below a predetermined safety level.

[0277] Figure 2 A general overview of the system is shown, with the ultrasound transducer located at a pigtail cable exiting from the implant housing, positioned close to the artery.

[0278] Figure 3 A typical pulsed mode ultrasound energy coupled to tissue is shown, and parameters of the ultrasound waves, such as peak negative pressure, carrier frequency, pulse duration, and pulse repetition frequency, may be varied based on data collected from the sensor.

[0279] Figure 4 A general implementation of an ultrasound implant of the system is shown.

[0280] Figure 5 Blood pulse wave sensing through an implant is shown. The pulse wave generates an acoustic signal. The implant detects the acoustic signal as it passes through an artery close to the implant.

[0281] Figure 6 A typical implementation of an on-skin control unit is shown. The on-skin unit may be in the form of a sleeve, a wearable device, etc.

[0282] Figure 7 A possible transmission method for an implant using load key modulation is shown.

[0283] Figure 8 The time delay measurement between the ECG and pulse wave signals is shown.

[0284] Figures 9 to 11Different embodiments of the present invention are schematically shown;

[0285] Fig.12 An embodiment of achieving multi-layer acoustic matching is shown;

[0286] Fig.13 An embodiment providing a passive implant is shown;

[0287] Fig.14 An example is shown in which NO induction is provided by utilizing an already implanted stent.

[0288] Fig.15 Embodiments are shown in which ultrasonic energy is provided at at least two substantially different frequencies of a carrier signal. DETAILED DESCRIPTION

[0289] The present invention, in some embodiments thereof, relates to a subcutaneous implantable device for delivering therapeutic energy to a patient. More specifically, it relates to an implantable ultrasound device adapted to affect the vascular endothelium to induce the release of nitric oxide (NO) and ATP. Thus, by applying ultrasonic energy to a blood vessel or tissue, the stimulated cavitation and shear stress promote angiogenesis in the patient. In addition, the present disclosure generally relates to the field of pulmonary artery denervation in the treatment of pulmonary hypertension and ischemic tissue.

[0290] Several cardiovascular diseases still lack effective treatments with significantly improved prognosis. One of the most prominent diseases is primary pulmonary hypertension (PH), a disease of increased pulmonary vascular resistance that often leads to right heart failure and premature death. Therapy using endothelin receptor antagonists offers hope to clinicians and patients. A major pathophysiological mechanism of pulmonary hypertension is the lack of nitric oxide in the pulmonary vasculature. Therefore, the present invention discloses a variety of implants suitable for applying ultrasound or vibration energy to induce NO release to treat pulmonary hypertension (PH).

[0291] Another important use of NO and ATP induction is in ischemic tissue. Therefore, the present invention also relates to improving the NO and ATP release in ischemic tissue (e.g., treating ischemic limbs or tissues affected by peripheral arterial disease) by applying ultrasound to the tissue under conditions that effectively increase the NO and ATP release in the ischemic tissue. Peripheral arterial disease is the most common form of atherosclerosis, affecting many people around the world. Due to such diseases, many people experience pain during physical activities (e.g., walking). Therefore, the present invention discloses a subcutaneous implant suitable for applying ultrasound or vibration energy to induce NO and ATP release to treat ischemic tissue.

[0292] One object of the present invention is to provide an ultrasonic subcutaneous implant that is capable of locally dilating a target artery and increasing downstream perfusion. Another object of the present invention is to provide a system comprising a plurality of implantable devices that are to be implanted in a patient's body adjacent to, near or within at least one blood vessel or tissue containing flowing blood, each of the plurality of implantable devices comprising a device for applying at least one energy source (e.g., an ultrasonic transducer) to the at least one blood vessel or tissue containing flowing blood, wherein the energy source is suitable for causing a physiological effect in the at least one blood vessel or tissue when applied; wherein at least one of the implantable devices communicates with at least one remote controller located outside the patient's body (e.g., worn by the patient), the at least one remote controller being suitable for programming and controlling the device for applying the at least one energy source.

[0293] Such wearable controllers may be integrated into wearable socks, shoes, gloves, clothing, hats, or into the patient's environment (e.g., furniture; e.g., chairs, sofas, beds, etc.), and any combination thereof.

[0294] Thus, each of the implants can locally dilate the target artery and increase downstream perfusion. The mechanism of action involves acoustic energy absorbed by endothelial cells and red blood cells causing the release of adenosine triphosphate (ATP) and nitric oxide (NO) into the bloodstream. NO dilates the artery and increases local blood flow and perfusion. For PAD / CLI patients with claudication, the implant will be placed a few centimeters (e.g., 2-3 cm) upstream of the ischemic area to locally increase tissue perfusion with the goal of alleviating hypoxic pain while walking, during physical exercise, or at rest. It should be noted that the positioning of the implant can initially be calculated by the half-life of NO and the flow rate in the specific vessel desired so that tailored positioning can be provided to ensure the most effective vasodilation effect is achieved at the desired distance.

[0295] According to one embodiment, at least one of the plurality of implantable devices is in communication with at least one battery that is implanted or located external to the patient.

[0296] According to one embodiment, the implant comprises or communicates with at least one sensor. The sensor is adapted to monitor at least one physiological state of the patient. Upon detecting a change, the device automatically activates to apply the energy (and thereby induce NO release), or the patient or any predetermined caregiver of the patient is notified of the change and the patient or caregiver activates the device.

[0297] According to one embodiment, the sensor is selected from the group consisting of: a sensor implanted in the patient, a sensor worn by the patient, a remote sensor outside the patient's body, and any combination thereof. For example, the sensor can also transmit to the implant outside the body (such as a wearable device), or it can be implanted elsewhere in the body. For example, a pacemaker that senses activity can also send a signal to our implant, so that the two devices work together and the heart rate increases while NO is released. Another example is other sensors used in cardiology (such as heart failure implantable sensors such as BSC HeartLogic and Abbot CardioMems).

[0298] According to other embodiments of the present invention, the implant is in communication with at least one controller adapted to receive information associated with at least one physiological state of the patient. According to another embodiment, the controller is in communication with at least one sensor adapted to sense information associated with at least one physiological state of the patient.

[0299] As used herein, with respect to quantities or values, the term "about" means "within ±10% of."

[0300] The terms "comprises / comprising", "includes / including", "has / having" and their cognates mean "including but not limited to".

[0301] Throughout this application, embodiments of the present invention may be presented in range format. It should be understood that the description in range format is for convenience and brevity only and should not be interpreted as a hard limitation on the scope of the present invention. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and individual values ​​within the range.

[0302] As used herein, the term "method" refers to ways, means, techniques and procedures for accomplishing a given task, including but not limited to those ways, means, techniques and procedures known to practitioners in the fields of chemistry, pharmacology, biology, biochemistry and medicine or readily developed based on known ways, means, techniques and procedures.

[0303] The present invention discloses an implant device comprising at least one transducer (eg, a piezoelectric transducer) that generates ultrasonic energy or vibration energy to simulate the application of shear forces on endothelial cells to induce NO and ATP production and release.

[0304] The implants will be placed in the vicinity of the ischemic tissue (ie, upper and lower extremities, i.e., arms and legs).

[0305] Activating the implant device to provide vibration or ultrasonic energy can primarily affect local NO release from endothelial cells. In addition, such devices can also induce ATP release. It should be noted that providing a device constructed and arranged to cause any other physiological effect selected from the group consisting of the following items is within the scope of the present invention: increased blood temperature; vasodilation; prolonged local nitric oxide effect; changes in red blood cell function; changes in oxygen release from hemoglobin; changes in blood pH; regulation of the immune response of blood leukocytes; regulation of coagulation and / or platelet function; changes in the function of heme catalytic enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis courses, and combinations thereof.

[0306] According to another embodiment, the device will be activated from outside the patient's body. Thus, according to this embodiment, a remote control located outside the patient's body is in communication with the device, adapted to activate the device and can be used by the patient himself or a "health care" provider to program and control the energy source, and therefore program and control the treatment regimen delivered to the patient (e.g., increase / decrease energy intensity, time, energy level, energy source, etc.).

[0307] According to one embodiment, an "on-demand" device / system will be provided. It should be noted that an "on-demand" device will only be activated when needed ("on-demand" basis). According to this embodiment, the device will be integrated / in communication with at least one sensor that monitors the patient's physiological state, so that when the physiological state changes, the device is activated or the device's treatment plan is modified.

[0308] According to this embodiment, the sensor of the "on demand" device can be selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, hydrophone, thermometer, manual activation, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0309] Each of the sensors is adapted to monitor the patient's physiological state and provide treatment accordingly. For example, an accelerometer would be used to indicate how the patient is positioned (e.g., when the patient is lying down, standing, walking, etc.). When a change is sensed (e.g., when the patient begins walking), the device is activated. In other words, the device activates "on demand" (when the patient is performing physical activity, such as walking) to induce NO release (and thereby increase oxidation levels, tissue perfusion within the tissue and reduce any pain associated therewith).

[0310] It is therefore a further object of the present invention to provide an implantable device as defined above, wherein the sensor is chosen so as to make it possible to estimate an indication of the level of physical activity or a change thereof, for example a change in the onset of walking or a change in a walking parameter such as speed, stride, cadence or a change from sitting to standing or lying down or from walking to running.

[0311] Within the scope of the present invention, the sensor is selected from the group consisting of: an accelerometer, impedance measurement, photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, a hydrophone, a thermometer, manual activation, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0312] Another example is an integrated impedance measurement sensor. According to this embodiment, vasodilation reduces the local impedance around the blood vessels due to the higher fluid volume compared to solid tissue. Therefore, such an impedance sensor will provide an indication of the NO / oxidation level in the tissue or blood vessels, and from which input can be retrieved regarding the required activation of the device or any modifications required in the device's treatment regimen (increased US intensity, treatment duration, etc.).

[0313] According to another embodiment, a subcutaneous implant or wearable device will include an ultrasonic transducer (and optionally, at least one ultrasonic receiver), a rechargeable battery, and a sensor array for measuring physiological parameters (such as patient activity or local tissue perfusion) and enabling "on-demand" therapy. For example, the device can sense walking and apply therapy at the right time to minimize pain. It should be noted that local tissue perfusion and oxygenation levels can be measured by impedance, PPG, ultrasonic echo, and any combination thereof.

[0314] As described above, according to one embodiment of the invention, the device communicates with an external charging unit to wirelessly charge the implant. According to another embodiment, the external unit will be able to download the data collected by the sensor.

[0315] The charging unit can be designed as a wearable unit on the patient. According to one embodiment, the charging unit will be worn once every predetermined time (e.g., once a day). According to another embodiment, the charging unit will be placed in a fixed position or integrated into the patient's natural environment (e.g., furniture, such as under a bed cover).

[0316] According to another embodiment of the present invention, a data controller (e.g., in the form of a cellular application) will be provided to enable both the clinician and the patient to control the device activities. The controller will connect to the data for monitoring and modify / maintain its treatment plan accordingly.

[0317] It should be noted that it is fully within the scope of the present invention to disclose a system comprising a plurality of such devices that are at least partially in communication with each other, wherein at least one device comprises at least one piezoelectric transducer or passive ferromagnetic element that generates ultrasonic energy or vibration energy to simulate the application of shear forces on endothelial cells, thereby inducing NO production and release.

[0318] According to one embodiment, the piezoelectric transducer is made of at least one material selected from the group consisting of: lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, a composite material, and any combination thereof.

[0319] The implant will be implanted subcutaneously in the vicinity of the ischemic tissue (ie, upper and lower extremities, i.e., arms and legs). Alternatively, the wearable device may be worn in the vicinity of the ischemic tissue.

[0320] Activating the implant to provide vibration or ultrasonic energy can primarily affect local NO release from endothelial cells. In addition, such implants can induce ATP release. It should be noted that providing a device constructed and arranged to cause any other physiological effect selected from the group consisting of the following items is within the scope of the present invention: increased blood temperature; vasodilation; prolonged local nitric oxide effect; changes in red blood cell function; changes in oxygen release from hemoglobin; changes in blood pH; regulation of the immune response of blood leukocytes; regulation of coagulation and / or platelet function; changes in the function of heme catalytic enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis treatment courses, and combinations thereof.

[0321] According to one embodiment of the present invention, the enhancement of the bioavailability of drugs can be utilized, for example, in chemotherapy. According to this embodiment, the device can be located near a solid tumor. Its activation during a course of systemic chemotherapy will cause an increase in blood flow to the tumor while providing chemotherapy.

[0322] According to another embodiment, the device will be activated from outside the patient's body. Thus, according to this embodiment, the remote control includes an electronic communication device external to the patient that communicates with at least one of the implants, adapted to activate the implant and can be used by a "health care" provider to program and control the energy source, and thereby control the treatment regimen delivered to the patient (e.g., increase / decrease amount, time, energy level, energy source, etc.).

[0323] Reference now Figure 1A , which shows an overall overview of the system (implant and on-skin controller) including the implant 101 and the on-skin unit 100.

[0324] like Figure 1AAs shown, in the implant 101, the coil is attached to its rear surface 113, forming an inductive link 112 with an on-skin sensor 114. The inductive link can be used for energy transmission from the on-skin unit 108 to the implant 101 through the skin 102, and as a communication channel for exchanging data and control between the on-skin unit 100 and the implant 101.

[0325] In some embodiments, the on-skin unit 100 may communicate with an external host via a wireless link 111 (eg, but not limited to, Bluetooth Low Energy (BLE)).

[0326] As shown in the figure, a blood pulse 105 flows in a blood vessel (e.g., an artery) 104. A stenosis 109 restricts flow in a blood vessel downstream 110. To enhance blood flow, the implant 101 generates ultrasonic energy 107, which is directed toward the blood vessel 104. The system can be programmed to emit ultrasonic energy automatically or upon command by the patient. Thus, a blood vessel portion 108 (which may be near a stenotic portion 109) is exposed to the ultrasonic energy 107.

[0327] Within the scope of the present invention, the ultrasonic energy may be in the form of a continuous wave or a pulsed wave.

[0328] According to one embodiment, ultrasonic energy is radiated from implant surface 106. In addition, surface 106 is also exposed to acoustic waves, such as those generated when pulse waves flow through blood vessel 104.

[0329] According to one embodiment, a smartphone application 102 may be used to communicate with the on-skin unit 100. In some embodiments, the application may be run on an external computer.

[0330] In some embodiments, the smartphone application 115 may communicate with the cloud-based program 103 for continuous monitoring and analysis.

[0331] Reference now Figure 1B , which shows essentially the same embodiment as shown in FIG. 1 a , but with the addition of at least one transducer 116 .

[0332] As described above, according to one embodiment, the implant includes or communicates with at least one sensor. The sensor is adapted to monitor at least one physiological state of the patient. Upon detecting a change, the device automatically activates to apply the energy (and thereby induce NO release), or the patient or any predetermined caregiver of the patient is notified of the change and the patient or caregiver activates the device.

[0333] According to one embodiment, the sensor is selected from the group consisting of: a sensor implanted in the patient, a sensor worn by the patient, a remote sensor outside the patient's body, and any combination thereof. For example, the sensor can also transmit to the implant outside the body (such as a wearable device), or it can be implanted elsewhere in the body. For example, a pacemaker that senses activity can also send a signal to our implant, so that the two devices work together and the heart rate increases while NO is released. Another example is other sensors used in cardiology (such as heart failure implantable sensors such as BSC HeartLogic and Abbot CardioMems).

[0334] According to other embodiments of the present invention, the implant is in communication with at least one on-skin controller; the controller is adapted to receive information associated with at least one physiological state of the patient. According to another embodiment, the controller is in communication with at least one sensor adapted to sense information associated with at least one physiological state of the patient. Furthermore, based on the physiological state of the patient, the controller can modify the treatment regimen of the applied ultrasonic energy.

[0335] According to one embodiment, an "on-demand" device / system will be provided. It should be noted that an "on-demand" device will only be activated when needed ("on-demand" basis). According to this embodiment, the device will be integrated / communicate with at least one sensor that monitors the patient's physiological state, so that when the physiological state changes, the device is activated or the device's treatment plan is modified.

[0336] According to this embodiment, the sensor of the "on demand" device can be selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, hydrophone, thermometer, manual activation, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0337] Each of the sensors is adapted to monitor the patient's physiological state and provide treatment accordingly. For example, an accelerometer would be used to indicate how the patient is positioned (e.g., when the patient is lying down, standing, walking, etc.). When a change is sensed (e.g., when the patient begins walking), the device is activated. In other words, the device activates "on demand" (when the patient is performing physical activity, such as walking) to induce NO release (and thereby increase oxidation levels, tissue perfusion within the tissue and reduce any pain associated therewith).

[0338] It is therefore a further object of the present invention to provide an implantable device as defined above, wherein the sensor is chosen so as to make it possible to estimate an indication of the level of physical activity or a change thereof, for example a change in the onset of walking or a change in a walking parameter such as speed, stride, cadence or a change from sitting to standing or lying down or from walking to running.

[0339] Reference now Figure 2 , which shows another embodiment of the present invention. According to this embodiment, the blood vessel 204 intended to be exposed to ultrasound energy is located at a deeper position, or when there is no direct line of sight of ultrasound between the implant 200 and the blood vessel portion 203 to be treated.

[0340] According to this embodiment, the ultrasound transducer 202 may be located in a pigtail cable 201 coupled to the implant 200 .

[0341] According to this embodiment, the implant 200 is controlled transcutaneously by an on-skin unit 205 via an inductive link 206 (ie at least one coil).

[0342] The on-skin unit may communicate with a smartphone 211 using a wireless link such as BLE 210 .

[0343] In another embodiment, the smartphone 211 may communicate with an external host program such as cloud-based software 212 .

[0344] According to this embodiment, the end of the pigtail is located near a blood vessel 204. Thus, one or more blood vessel portions 203 are exposed to the ultrasonic waves generated by the ultrasonic transducer 202.

[0345] The ultrasonic transducer 202 may be a piezoelectric transducer, an electrostatic transducer, or any type of ultrasonic transducer capable of generating sufficient peak negative pressure to induce shear forces in the vessel wall.

[0346] According to another embodiment, the ultrasonic transducer 202 may also be used as a feedback sensor to allow monitoring of the ultrasonic energy generated by the ultrasonic transducer.

[0347] In another embodiment, when the blood pulse wave 213 flows in the artery 204 near the pigtail 201, the ultrasonic transducer 202 may be used to sense the blood pulse wave.

[0348] In another embodiment, a dedicated acoustic sensor may be used in the pigtail 201 for sensing.

[0349] In another embodiment, the acoustic sensor can sense the pulse wave 213 flowing through the downstream 208 of the artery 204.

[0350] In another embodiment, a thermal sensor such as a thermistor may be used in the pigtail 201 for sensing.

[0351] In another embodiment, more than one acoustic sensor may be employed in the pigtail 201 to sense the pulse wave velocity in the blood vessel 204 .

[0352] Reference now Figure 3 , which shows pulsed mode ultrasonic energy.

[0353] The pulse wave duration PW 300 may be as short as 10 cycles. The pulse repetition frequency 301 may be such that the duty cycle may be as low as 10%. The ultrasonic energy pulse may have a peak negative pressure 303 of up to 5 MPa.

[0354] In another embodiment, the carrier frequency of the ultrasonic wave may be between 10 kHz and 2 MHz.

[0355] In some embodiments, the ultrasonic carrier frequency 302 may be modulated.

[0356] In some embodiments, the pulse wave may consist of more than one carrier frequency to increase the shear forces exerted on the blood vessel.

[0357] In some embodiments, the ultrasound pulse amplitude may be amplitude modulated.

[0358] In some embodiments, the pulse repetition rate (PRF) 301 and PW 300 length and amplitude 303 may be adjusted based on the patient's requirements.

[0359] In some embodiments, the PRF 301, PW 300 length, and amplitude 303 may be automatically adjusted without patient intervention.

[0360] Reference now Figure 4 , which shows an overall overview of the implant 400 implementation.

[0361] According to this embodiment, the implant may have a non-metallic coating, such as PEEK 401.

[0362] In some embodiments, PEEK may be coated with parylene.

[0363] If the width of the front surface 403 to which the ultrasound transducer is attached internally has a thickness of, for example, about one quarter λ, then the front surface can act as an acoustic matching layer, where λ is the ultrasonic wavelength in PEEK.

[0364] The front surface 403 is oriented toward the blood vessel to be treated to allow the ultrasound energy to hit the intended blood vessel.The radiating surface 403 also serves as a pressure wave receiving surface, such as for sensing pulse wave acoustic signals, or detecting ultrasound reflections.

[0365] According to one embodiment, the rear surface of the implant uses a coil 402 as part of the inductive link with the unit on the skin. The energy harvested by the coil 402 can directly drive the ultrasound transducer 404. In such a case, the auxiliary power 409 mainly needs to be rectified and filtered by the power harvesting unit 407.

[0366] Alternatively or additionally, the AC power collected by the coil 402 may be converted into a DC voltage DC by a power collection unit 407. The DC voltage is stored in a capacitor storage 406. The energy collected at the capacitor storage 406 is used to drive the internal ultrasound driver 405. The DC voltage is also used to power the implant circuitry via an auxiliary power supply 409.

[0367] According to one embodiment, the analog conditioning stage 412 may be used to amplify and filter the pulse wave signal. To protect the analog circuit from the higher voltage used to drive the ultrasound transducer 404, a T / R switch 411 may be employed. The T / R switch may be controlled by the microcontroller stage 408, such as by the GPIO 410. The microcontroller samples the analog signal of the pulse wave and may send it to the on-skin unit via the sensing channel.

[0368] The ultrasonic transducer 404 may have a PZT element, preferably but not limited to hard lead zirconate titanate PZT, to reduce internal power loss.

[0369] In some embodiments, the piezoelectric may have a non-uniform transverse polarization, such as a Gaussian-shaped polarization, in order to reduce side lobes in the ultrasound energy.

[0370] In some embodiments, the ultrasound transducer 404 may include a PZT array.

[0371] In some embodiments, the PZT array can be driven as a phased array.

[0372] According to one embodiment, the ultrasound waves include more than one carrier frequency, which can generate higher shear forces in the vessel wall. Therefore, in some embodiments, the PZT array 404 can be driven by more than one carrier frequency. For example, a portion of the array is driven at one carrier frequency, while other portions are driven at a second carrier frequency.

[0373] In some embodiments, an embedded microcontroller 408 may be employed. The microcontroller may control the transmit receive protection switch 411, collect sensor information, control the ultrasound driver 405, and communicate with the on-skin unit via the communication block 415.

[0374] In some embodiments, accelerometer sensor 414 may be employed to sense patient motion.

[0375] In some embodiments, thermal sensor 413 may be used as a protection device against over-temperature of the implant circuitry and its envelope.

[0376] The blood pulse wave contains valuable information about blood flow, such as blood flow velocity, pulse pressure level, augmentation index, etc. Therefore, sensing it may be beneficial for long-term monitoring of blood flow in the treatment vessel and downstream tree.

[0377] Reference now Figure 5 , which shows another embodiment of the present invention, in which a pulse wave sensing configuration is performed by an implant 500.

[0378] The blood pulse wave 502 flowing in a desired blood vessel (eg, artery) 503 causes the vessel wall to expand radially 504 due to the elasticity of the vessel.

[0379] The transient expansion and contraction of the blood vessel wall generates acoustic waves 501 which propagate through the tissue also toward the implant's acoustic receiving surface 509. Thus, the ultrasound transducer 505 can also be used as an acoustic sensor.

[0380] Alternatively, a dedicated acoustic sensor may be employed, such as a piezoelectric element made of piezoelectric lead zirconate titanate (PZT) or polyvinylidene fluoride or polyvinylidene fluoride (PVDF) film. To protect the analog conditioning circuit 507 from the high drive voltage, a protection circuit in the form of a T / R switch 506 may be employed. The amplified analog signal 508 may be sampled by the implant microcontroller and sent to the on-skin unit for further processing.

[0381] Reference now Figure 6 , which shows a general overview of a possible on-skin controller 600 located on the skin 601. According to this embodiment, the controller employs a coil 602 that forms an inductive power and communication link with the implant coil.

[0382] A coil driver 611 is employed to drive the desired current to the coil. The driver 611 is powered by a power stage 610, which can be used to boost the voltage of the electrical energy source 609 to a desired level.

[0383] The energy source may be a non-rechargeable or rechargeable battery, which may be charged through port 612 .

[0384] The on-skin controller 600 may employ a microcontroller 604 to facilitate a communication channel with the implant through the induction coil 602 , and may also incorporate a communication front end 606 to communicate with external systems through a wireless link such as Bluetooth 607 .

[0385] According to another embodiment, the microcontroller 604 may protect the receive chain 605 by employing a transmit / receive electronic switch 603 .

[0386] According to another embodiment, the on-skin unit may also employ a plurality of sensors 608, such as an accelerometer capable of detecting patient motion, a thermal sensor (such as a thermistor for temperature protection), and an electrocardiogram (ECG) sensor. The ECG sensor helps sense the propagation delay changes of the pulse wave in the treated artery compared to the ECG pulse.

[0387] Various sensor outputs, such as heart rate, pulse wave shape, pulse wave velocity, core body temperature, and delay between the ECG and pulse wave signals in the treatment artery, can be analyzed locally by an on-skin controller to adjust ultrasound energy parameters, or sent upstream for further processing and long-term data collection (e.g., via cloud-based software).

[0388] Reference now Figure 7 , which shows a possible mechanism to facilitate data extraction over an inductive link. Bitstream data 700 modulates an electronic switch 701, such as a silicon switch, to connect / disconnect an impedance 702 across an implant coil 703. The switch load impedance 702 draws a switching current pulse that can be sensed by the coil on the skin.

[0389] Reference now Figure 8 , which shows the time delay 802 between the ECG signal 800 and the pulse wave signal 801.

[0390] The time delay 802 may vary depending on the vessel being treated and downstream changes in blood flow resistance. Typically, the time delay between the R wave 803 of the ECG signal to the start of the upstroke signal 804 of the pulse wave is measured.

[0391] Furthermore, according to another embodiment, pulse pressure 807 is measured from the pulse wave signal as the difference between the systolic peak 805 and the end-diastolic pressure. Systolic overshoot time 804 is another possible parameter that depends on the downstream resistance to blood flow. The overall information that can be extracted from the pulse wave and ECG can be used to automatically adjust the ultrasonic energy parameters generated by the implant or pigtail, and can also be used for long-term monitoring of the patient's blood flow quality in the artery and downstream.

[0392] Reference now Fig. 9 , which shows an array 100 of two implants 10 in communication with an external device (in this case a coil) 20 located on the patient's skin 30. When the transducer is activated, mechanical vibrations 40 are induced to the blood vessel 50. Those skilled in the art will appreciate that while only two implants are shown, any number of implants may be utilized.

[0393] According to this embodiment, utilizing multiple implants facilitates the use of small sized implants.

[0394] Furthermore, by providing multiple implants, the position and orientation of each of the implants can be controlled. Furthermore, the control of the position and orientation of each of the implants provides a focus capability that can be achieved on a desired blood vessel.

[0395] According to another embodiment of the present invention, since there are multiple implanted transducers, each transducer can operate in a different frequency range (e.g., a first range of 20 kHz to about 10 MHz and a second range of 20 kHz to about 10 MHz). According to another embodiment of the present invention, all transducers operate in the same frequency range.

[0396] The controller (external unit) may be an electrical oscillator which may generate a signal in the ultrasonic spectrum (eg down to 20 kHz or up to 10 MHz).

[0397] According to other embodiments, the external controller is adapted to charge the implant.According to another embodiment, the charging is performed by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive and any combination thereof.

[0398] According to one embodiment, the controller comprises at least one coil.

[0399] Once the controller's signal is provided to the transducer, the transducer emits acoustic energy from its surface, as is well known to those skilled in the art.

[0400] The controller may control at least one selected from the group consisting of: the amplitude and therefore the intensity or power of the acoustic waves emitted by the transducer, the timing (start and period), a possible refractory period (i.e., a new cycle is not started until at least X minutes have passed since the previous cycle), the directionality of the signal (one transmitter may stimulate more than one vessel that is slightly distant from each other, and the phased array may direct the stimulation to a different vessel each time), and any combination thereof. In other embodiments, if the transducer comprises more than one transducer element, the controller may also control the phase component of the drive signal to the respective transducer elements of the transducer arrangement, for example to control the shape or size of the focal zone generated by the transducer element, and / or to move the focal zone to a desired location. For example, the controller may control the phase shift of the drive signal to adjust the focal length (i.e., the distance from the face of the transducer to the center of the focal zone). In further embodiments, the controller may be configured to operate the transducer for a predetermined duration. Alternatively or additionally, the controller may be configured to automatically shut down the transducer when the use of the transducer exceeds the predetermined time.

[0401] It should be noted that the controller can be external to the patient or integrated within the implant. In this way, when multiple implants are utilized and implanted, one implant (with a controller integrated therein) can control the remaining implants.

[0402] As described above, according to one embodiment of the present invention, the controller can communicate with at least one sensor selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, a hydrophone, a thermometer, a core temperature of the body, a heart pulse rate, a pulse wave characteristic, a glucose sensor, a manual activation, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof. In such embodiments, the device is an "on-demand" device. In other words, an "on-demand" device is activated only when needed ("on-demand"). According to this embodiment, the sensor monitors the patient's physiological state so that when the physiological state changes, the controller signals the transducer to emit an acoustic signal (or modify one of the parameters of the acoustic signal).

[0403] As specified, each of the sensors is adapted to monitor the patient's physiological state and provide treatment accordingly. For example, an accelerometer would be used to indicate how the patient's position is (e.g., when the patient is lying down, standing, walking, etc.). When a change is sensed (e.g., when the patient begins to walk), the device is activated. In other words, the device activates "on demand" (when the patient is performing physical activity, such as walking) to induce NO release (and thereby increase oxidation levels, tissue perfusion within the tissue and reduce any pain associated therewith).

[0404] According to one embodiment of the present invention, the target tissue being treated is a target tissue that has been affected by peripheral arterial disease (and is located in an upper or lower extremity of the patient). In other embodiments, the target tissue may be associated with other diseases or medical conditions (such as pain caused by movement) and may be located at other parts of the patient.

[0405] Once the device is positioned at its predetermined location, the transducer (based on a signal from the controller) delivers ultrasonic energy to the target tissue. The transducer may emit acoustic energy in a continuous manner or alternatively in pulses. In some embodiments, the controller may also control the phase of the transducer, the operating frequency, the temperature of the tissue (to ensure that the tissue does not overheat), and / or the operating amplitude.

[0406] According to another embodiment of the present invention, pulse wave characteristics and pulse wave velocity measurements may be measured to indicate arterial dilation and increased blood perfusion. Fig.10, which illustrates such acoustic sensing of pulse wave characteristics. As shown, the incident and reflected waves (11 and 12, respectively) result in vibrations 60 that travel through a blood vessel 50 and can be sensed by an external controller (or a microcontroller embedded within the implant). Analysis of the waves can provide indications regarding dilation and increased blood perfusion and regarding optimizing the orientation of the implant relative to the blood vessel. Thus, the analysis can aid in alignment of the position of at least one of the plurality of implants relative to the at least one blood vessel or tissue containing flowing blood.

[0407] According to another embodiment, the alignment is indicated (to the patient or caregiver) by at least one indication means selected from the group consisting of an audio means, a visual means, a tactile means, and any combination thereof.

[0408] According to another embodiment, the analysis of the at least one pulse wave feature indicates whether the desired physiological effect (vasodilation and increased blood perfusion) was indeed achieved.

[0409] According to another embodiment of the present invention, a second instantaneous wearable controller is utilized to facilitate pulse wave velocity flow measurement. Fig.11 , which illustrates such an embodiment.

[0410] According to this embodiment, the implant 10 communicates with a main external unit (controller) 20. The main external unit 20 is wired via a wire 70 (however, it can be a wireless connection) to at least one second wearable unit 80. The second wearable unit 80 facilitates intermittent pulse wave flow sensing. According to one embodiment, the second wearable unit 80 may not be used continuously but only from time to time.

[0411] Alternatively, the second wearable unit 80 can serve as a battery holder for the thickness and weight of the main external unit (controller) 20.

[0412] According to one embodiment, an "on-demand" device will be provided. It should be noted that an "on-demand" device will only be activated when needed (an "on-demand" basis). According to this embodiment, the device will be integrated with at least one sensor that monitors the patient's physiological state, so that when the physiological state changes, the device is activated or the device's treatment plan is modified.

[0413] According to this embodiment, the sensor of the "on demand" device can be selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, manual activation, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0414] Each of the sensors is adapted to monitor the patient's physiological state and provide treatment accordingly. For example, an accelerometer would be used to indicate how the patient is positioned (e.g., when the patient is lying down, standing, walking, etc.). When a change is sensed (e.g., when the patient begins walking), the device is activated. In other words, the device activates "on demand" (when the patient is performing physical activity, such as walking) to induce NO release (and thereby increase oxidation levels, tissue perfusion within the tissue and reduce any pain associated therewith).

[0415] It is therefore a further object of the invention wherein the sensors are selected so as to enable an estimation of the level of physical activity or an indication of a change thereof, for example a change in the onset of walking or a change in a walking parameter such as speed, stride, cadence or a change from sitting to standing or lying down or from walking to running.

[0416] Within the scope of the present invention, the sensor is selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, manual activation, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof.

[0417] Another example is an integrated impedance measurement sensor. According to this embodiment, vasodilation reduces the local impedance around the blood vessels due to the higher fluid volume compared to solid tissue. Therefore, such an impedance sensor will provide an indication of the NO / oxidation level in the tissue or blood vessels, and from which input can be retrieved regarding the required activation of the device or any modifications required in the device's treatment regimen (increased US intensity, treatment duration, etc.).

[0418] According to another embodiment of the invention, the implant will utilize multiple piezoelectric transducers. According to another embodiment, the multiple piezoelectric transducers will be arranged in a phased array. Such an array will be able to fine-tune the position of the device relative to the treated vessel. According to this embodiment, each transducer will be activated / deactivated to be able to align the position of the device relative to the vessel to maximize NO induction.

[0419] According to a further embodiment, at least one of the piezoelectric transducers is shielded by Gaussian apodization and material polarization.

[0420] According to another embodiment, the piezoelectric transducer is made of at least one material selected from the group consisting of: lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, a composite material, and any combination thereof.

[0421] According to another embodiment, in order to reduce the overall implant thickness, multi-layer acoustic matching is implemented. According to this embodiment, the implant package is part of the acoustic matching layer. Now referring to Fig.12 , which illustrates such an embodiment.

[0422] According to this embodiment, the implant is encapsulated in an envelope made of acoustic impedance matching; in particular a layer of polyetheretherketone PEEK, 15 .

[0423] As shown in the figure, the first acoustic impedance matching layer 16 is disposed at the most distal end and closest to the blood vessel. According to this embodiment, the first acoustic impedance matching layer 16 is sandwiched between at least two layers of glue (e.g., penloc GTI) 14, and the transducer (e.g., piezoelectric element) 13 is positioned therebehind.

[0424] According to this embodiment, various piezoelectric materials may be used, which are selected from hard lead zirconate titanate, PZT (such as PZT8), lead magnesium niobate-lead titanate, PMN-PT, composite materials, and any combination thereof.

[0425] According to another embodiment, at least one of the implants comprises an ultrasound transducer (and optionally at least one ultrasound receiver), a rechargeable battery, and a sensor array for measuring a physiological parameter (eg, patient activity or local tissue perfusion).

[0426] According to another embodiment, "on-demand" therapy can be performed. For example, the device can sense walking and apply therapy at the right time to minimize pain.

[0427] It should be noted that local tissue perfusion and oxygenation levels can be measured by impedance, PPG, ultrasound echo, and any combination thereof.

[0428] As described above, according to one embodiment of the present invention, the implant communicates with an external charging unit to wirelessly charge the implant.

[0429] According to some embodiments, the charging unit may be designed as a wearable unit worn by the patient. According to one embodiment, the charging unit will be worn once at predetermined intervals (e.g., once a day). According to another embodiment, the charging unit will be placed in a fixed location or integrated within the patient's natural environment (e.g., furniture, such as under a bed cover).

[0430] According to some embodiments, the charging unit will be performed by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive and any combination thereof. According to one embodiment, the charging unit (ie, the external controller) includes at least one coil.

[0431] According to other embodiments, the external controller will acoustically sense at least one pulse wave feature reflected from at least one of the plurality of implants. Within the scope of the present invention, analysis of the at least one pulse wave feature facilitates alignment of the position of at least one of the plurality of implants relative to a treated vessel or tissue containing flowing blood. It should also be understood that within the scope of the present invention, analysis of the at least one pulse wave feature indicates whether a desired physiological effect (e.g., arterial dilation and increased blood perfusion) has been induced.

[0432] According to one embodiment, this alignment is indicated (to the caregiver user) audio-wise, visually, tactilely, and any combination thereof.

[0433] According to other embodiments, at least one of the implants will include at least one processor (or controller). According to one embodiment, such a processor may acoustically sense at least one pulse wave feature reflected from at least one of the plurality of implants. Within the scope of the present invention, analysis of the at least one pulse wave feature facilitates alignment of the position of at least one of the plurality of implants relative to a treated vessel or tissue containing flowing blood.

[0434] It is also to be understood that within the scope of the present invention, analysis of the at least one pulse wave characteristic indicates whether a desired physiological effect (eg, arterial dilation and increased blood perfusion) has been induced.

[0435] According to one embodiment, this alignment is indicated (to the caregiver user) audio-wise, visually, tactilely, and any combination thereof.

[0436] According to other embodiments, at least one of the implants comprises at least one processor adapted to control at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, temperature of tissue, timing, duration of said energy source, and any combination thereof. According to such embodiments, said implants communicate with each other; thereby, depending on the parameter, the treatment regimen can be adjusted accordingly.

[0437] According to other embodiments, the processor communicates with at least one sensor adapted to sense information associated with at least one physiological state of the patient. The sensor may be any sensor selected from the group consisting of: a sensor implanted in the patient, a sensor worn by the patient, a remote sensor external to the patient's body, and any combination thereof.

[0438] According to other embodiments, the processor is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) modifying the treatment provided to the patient; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof.

[0439] According to another embodiment, the external unit will be able to download data collected by the sensor in addition to the ability to charge the implant. According to some embodiments of the present invention, data downloading will be achieved by means known in the art; for example, similar to RFID reading methods.

[0440] According to another embodiment of the present invention, a data controller (e.g., in the form of a cellular application) will be provided to enable both the clinician and the patient to control the device activities. The controller will connect to the data for monitoring and modify / maintain its treatment plan accordingly.

[0441] According to some embodiments, the ultrasound implant will be placed a few centimeters (e.g., 2-3 cm) away from an area of ​​intermittent or chronic ischemia or constriction (decreased perfusion), or in an area where permanent or intermittent enhancement of local perfusion is desired. The initial target arteries may be the iliac arteries and the superficial femoral artery (SFA). After placement of the implant, the treating physician will set the operating parameters, activate the implant and verify increased perfusion at the area of ​​ischemia or constriction (decreased perfusion).

[0442] If the patient is found to be non-responsive (e.g., due to high levels of calcification in the artery not allowing dilation), additional implants may be considered. Additionally, the patient's physiological response to local NO release may be tested using external ultrasound to verify if a large proportion is found to be non-responsive (e.g., due to high levels of calcification in the artery not allowing dilation).

[0443] Therefore, it should be noted that external ultrasound is used to test the patient's physiological response to local NO release, verifying whether the device will be effective and estimating the effective NO dose (which will later be used to set the device's operating parameters) and its response.

[0444] According to another embodiment of the invention, tissue compliance or endothelial response to US application will be checked prior to utilizing the device. According to this embodiment, auxiliary systems (e.g., Doppler ultrasound, ultrasound, MRI, CT) will be utilized. According to this embodiment, Doppler ultrasound devices can be used to measure the degree of perfusion, which provides a qualitative measure of the increase in blood flow caused by the ultrasound treatment provided by the device.

[0445] According to another embodiment of the present invention, the tissue compliance or endothelial response to US application will be checked before implantation. According to this embodiment, auxiliary systems (e.g., Doppler ultrasound, ultrasound, MRI, CT) will be utilized. According to one embodiment, the auxiliary systems are Doppler ultrasound, ultrasound, MRI, CT, etc. According to this embodiment, Doppler ultrasound will be applied at the desired position (the position where the implant is considered to be implanted), and then at least one parameter selected from the group consisting of the following items will be monitored to verify whether there is any improvement: an increase in blood flow (by analyzing the reflected sound waves from red blood cells), NO levels, oxidation levels, tissue perfusion, verification of the optimal position of the device, and any combination thereof. If one of the parameters (e.g., blood flow) does improve; this will indicate that the patient is responding to the effect of the device and is therefore adapted to such use. Therefore, a method for the adaptability of a patient to such treatment is provided. Alternatively, the optimal position of the implant can be verified using this method and the treatment parameters and regimen can be optimized to achieve optimal treatment.

[0446] Thus, according to this embodiment, at least one parameter of the device selected from the group consisting of the intensity or power of the applied US energy, the timing, its duration, its frequency and any combination thereof is changed (while keeping the other parameters constant) and its effect on the treated tissue or vessel is examined via auxiliary systems (Doppler ultrasound, ultrasound, MRI, CT). In this way, a treatment plan tailored and optimized for the patient can be established.

[0447] According to one embodiment, the implant according to the invention comprises at least one transducer. According to other embodiments, the transducer is a piezoelectric transducer generating ultrasonic energy, at least one passive ferromagnetic element, or any combination thereof.

[0448] According to other embodiments, the transducer may be disposed on a platform capable of supporting it. The platform may be substantially rigid, semi-rigid, or substantially flexible, and may be made of a variety of materials such as plastics, polymers, metals, and alloys. Electrodes and wires may also be provided in a known manner for coupling the transducer to a control.

[0449] According to one embodiment of the present invention, the transducer includes one or more transducer elements. Each of the transducer elements can be a one-piece piezoelectric ceramic component, or alternatively, composed of a mosaic arrangement (e.g., a phased array) of multiple small piezoelectric ceramic elements. The piezoelectric ceramic component or piezoelectric ceramic element can have a variety of geometric shapes, such as hexagons, triangles, squares, etc. The material used to construct the transducer element can be a composite material, a piezoelectric ceramic, or any other material that can convert an electrical signal into an acoustic wave. The transducer element is coupled to a controller for generating and / or controlling the acoustic energy emitted by the transducer element.

[0450] According to other embodiments, the piezoelectric body is made of at least one material selected from the group consisting of: lead zirconate titanate, lead magnesium niobate-lead titanate, hard PZT, a composite material, and any combination thereof.

[0451] According to another embodiment of the present invention, a passive implant is provided, according to which an electromagnetic acoustic transducer EMAT is provided to induce ultrasonic vibrations. Fig.13 , which illustrates such an embodiment.

[0452] As shown, the implant 10 is made of EMAT (made of ferromagnetic material) to induce ultrasonic vibrations 19 into a blood vessel 50 .

[0453] An external control (shown as a coil) 20 generates an alternating electromagnetic flux 21 which induces mechanical vibrations from the EMAT to the blood vessel 50 .

[0454] According to another embodiment of the present invention, NO induction is provided by utilizing an already implanted stent. Fig.14 , which shows such an embodiment. As shown in the figure, ultrasonic vibrations are induced using a ferromagnetic stent 10 previously implanted in a patient. As previously described, an external unit (external controller (shown as a coil in the figure)) 20 generates an alternating flux that induces an electric current in the ferromagnetic surface of the stent 10. This in turn causes mechanical vibrations on the blood vessel 50.

[0455] As indicated above, the controller may control at least one selected from the group consisting of: the amplitude and therefore the intensity or power of the acoustic waves emitted by the transducer, the timing (start and period), a possible refractory period (i.e., a new cycle is not started until at least X minutes have passed since the previous cycle), the directionality of the signal (one transmitter may stimulate more than one vessel that is slightly distant from each other, and the phased array may direct the stimulation to a different vessel each time), and any combination thereof. In other embodiments, if the transducer comprises more than one transducer element, the controller may also control the phase component of the drive signal to the respective transducer elements of the transducer arrangement, for example to control the shape or size of the focal zone generated by the transducer element, and / or to move the focal zone to a desired location. For example, the controller may control the phase shift of the drive signal to adjust the focal length (i.e., the distance from the face of the transducer to the center of the focal zone). In further embodiments, the controller may be configured to operate the transducer for a predetermined duration. Alternatively or additionally, the controller may be configured to automatically shut down the transducer when the use of the transducer exceeds the predetermined time.

[0456] It should be noted that the controller can be external to the patient or integrated within the implant. In this way, when multiple implants are utilized and implanted, one implant (with a controller integrated therein) can control the remaining implants.

[0457] As described above, according to one embodiment of the present invention, the controller can communicate with at least one sensor selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, hydrophone, thermometer, core temperature, heart rate, pulse wave characteristics, glucose sensor, manual activation, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, any sensor associated with a dialysis machine, and any combination thereof. In such embodiments, the implant device is an "on-demand" device. In other words, an "on-demand" device is activated only when needed ("on-demand"). According to this embodiment, the sensor monitors the patient's physiological state so that when the physiological state changes, the controller sends a signal to the transducer to transmit an acoustic signal (or modify one of the parameters of the acoustic signal).

[0458] As specified, each of the sensors is adapted to monitor the patient's physiological state and provide treatment accordingly. For example, an accelerometer would be used to indicate how the patient's position is (e.g., when the patient is lying down, standing, walking, etc.). When a change is sensed (e.g., when the patient begins to walk), the device is activated. In other words, the device activates "on demand" (when the patient is performing physical activity, such as walking) to induce NO release (and thereby increase oxidation levels, tissue perfusion within the tissue and reduce any pain associated therewith).

[0459] According to one embodiment of the present invention, the target tissue being treated is a target tissue that has been affected by peripheral arterial disease (and is located in an upper or lower extremity of the patient). In other embodiments, the target tissue may be associated with other diseases or medical conditions (such as pain caused by movement) and may be located at other parts of the patient.

[0460] Once the device is positioned at its predetermined location, the transducer (based on a signal from the controller) delivers ultrasonic energy to the target tissue. The transducer may emit acoustic energy in a continuous manner or alternatively in pulses. In some embodiments, the controller may also control the phase of the transducer, the operating frequency, the temperature of the tissue (to ensure that the tissue does not overheat), and / or the operating amplitude.

[0461] As described above, the acoustic energy delivered by the transducer is at least partially absorbed by the tissue and causes mechanical stimulation of the endothelial cells through compression and wall shear stress in the blood vessels, thereby stimulating the production of endothelial nitric oxide synthesis (eNOs). Elevated nitric oxide levels are believed to have multiple effects on tissues, including inhibiting leukocyte and platelet adhesion, controlling vascular tone and maintaining an anti-thrombotic interface between blood flow and the vessel wall, increasing capillary circumference (vasodilation) and / or increasing blood flow (perfusion), treating pulmonary HP. Such effects, in turn, help to reduce pain at the tissue and allow patients to recover through exercise.

[0462] According to another embodiment of the present invention, an auxiliary system is utilized. According to this embodiment, the auxiliary system is at least one selected from Doppler ultrasound, ultrasound, MRI, CT, and any combination thereof. According to this embodiment, Doppler ultrasound will be applied at the desired location, and then at least one parameter selected from the group consisting of the following items will be monitored to verify whether there is any improvement: blood flow (by analyzing reflected sound waves from red blood cells), NO levels, oxidation levels, tissue perfusion, verification of the optimal position of the device, and any combination thereof. If one of the parameters (e.g., blood flow) does improve; this will indicate that the patient is responding to the effect of the device and is therefore adapting to such use. Therefore, a method for the adaptability of patients to such treatment is provided.

[0463] According to another embodiment of the present invention, an auxiliary system (e.g., Doppler ultrasound, ultrasound, MRI, CT) will be used to optimize the treatment plan. According to this embodiment, Doppler ultrasound (or ultrasound, MRI, CT) will be applied at the desired position (the position where the implant is considered to be implanted), and then at least one parameter selected from the group consisting of the following items will be monitored to establish the optimized treatment parameters: an increase in blood flow (by analyzing the reflected sound waves from red blood cells), NO levels, oxidation levels, tissue perfusion, verification of the optimal position of the device, and any combination thereof. Therefore, according to this embodiment, at least one parameter of the group consisting of the intensity or power of the applied US energy, timing, the temperature of the treated tissue (to ensure that it does not overheat), its duration, its frequency, and any combination thereof of the implant device is changed (while keeping other parameters constant), and its effect on the treated tissue or blood vessel is checked via the auxiliary system (Doppler ultrasound or ultrasound, MRI, CT). In this way, a treatment plan tailored and optimized for the patient can be established.

[0464] It should be noted that according to this embodiment, during a treatment session, the energy intensity or dose delivered by the transducer at the tissue is maintained below a specified threshold (e.g., by using an appropriate drive scheme and / or by selecting appropriate operating parameters, such as operating frequency, operating amplitude, etc.), thereby protecting the tissue from damage by acoustic energy.

[0465] As described above, in any of the embodiments described herein, the implant may further include one or more additional ultrasonic transducers. The transducers may be positioned in a side-by-side configuration to form a line. For example, in some embodiments, the system includes several transducers, each of which operates with a different transmitted sound wave. It should be noted that providing multiple transducers allows for simultaneous treatment of multiple target areas or treatment with different treatment regimens (e.g., each transducer operates with different power, intensity, timing, duration, etc.).

[0466] In some cases, the controller can be configured to control the transducers so that the sound waves emitted by the corresponding transducers interact in a desired manner. For example, in some embodiments, the relative phase between the transducers can be varied. In one embodiment, adjacent transducers are driven alternately in phase and out of phase. Because the sound fields from adjacent transducers may overlap and due to resonance, the intensity distribution within the patient may form a series of interfering maxima and minima. By changing the phase relationship between the transducers, the positions of these pecks and nulls can be reversed, thereby providing overall uniform (or substantially uniform) sound penetration at the target tissue or blood vessel. In other embodiments, the operating frequency of one or more transducers can be changed to move the interference pattern of the sound field.

[0467] In other embodiments, the transducers can be moved relative to the patient. In such embodiments, the position of at least one of the transducers can be optimized relative to the desired treatment tissue or vessel.

[0468] In other embodiments, at least one of the implants is adapted to apply ultrasonic energy at at least two substantially different frequencies of the carrier signal. Fig.15 , which shows such an embodiment. In such an embodiment, the implant 10 includes at least one piezoelectric transducer 23, which is adapted to generate the ultrasonic energy at one of the two substantially different frequencies of the carrier signal; and at least one electromagnetic acoustic transducer (EMAT) 24 is mechanically coupled to the at least one piezoelectric transducer 24, the at least one piezoelectric transducer being adapted to generate the ultrasonic energy in a different second frequency range. As described above, upon activation of the external controller 20, mechanical vibrations (acoustic waves) 19 are induced on the blood vessel 50.

[0469] In one embodiment, the first range is selected from about 20 kHz to about 10 MHz, and the second range is selected from about 20 kHz to about 10 MHz.

[0470] In other embodiments, at least one electromagnetic acoustic transducer includes at least one ferromagnetic plate.

[0471] In other embodiments, the implant is encapsulated in at least one layer of polyetheretherketone (PEEK) 22 .

[0472] According to another embodiment of the present invention, multiple implants are utilized. One of the multiple implants is very thin, includes at least one coil and is positioned close to the skin; and at least one second implant includes a transducer (piezoelectric element) positioned close to the blood vessel. The two implants are wired coupled to each other. According to another embodiment, the thin implant (which includes at least one coil and is positioned close to the skin) is wired to multiple implants, each implant being positioned at a different position and orientation relative to the blood vessel. Such embodiments provide multiple treatment points along the blood vessel (with a wide range of effects), and as described above, the pulse wave characteristics can be analyzed to optimize the treatment parameters and the positioning (e.g., alignment) of at least one of the implants relative to the blood vessel. It should be noted that the implant device can be used to treat:

[0473] ●CLI / PAD - Improved healing in patients after revascularization. In this application, the implant will be activated continuously or intermittently after revascularization.

[0474] ●Improving wound healing in patients with PAD, including avoiding leg amputation.

[0475] ●Local and long-term treatment of pulmonary hypertension.

[0476] - Treating severe asthma patients (those who do not respond to standard asthma inhalers) by affecting the bronchial arteries. It should be noted that in such applications, any breathing or sound-related parameter that could provide an indication of an asthma attack could trigger activation of the implant device to relieve bronchospasm.

[0477] ● Improving blood flow to the brain during stroke by producing NO in the carotid arteries (using an external ultrasound device). ● "Local Viagra" - increasing blood flow to the penis to maintain an erection without the systemic side effects of sildenafil (Viagra pills).

[0478] Improved bioavailability of drugs – It should be noted that for this application, the timing of drug administration (oral, IV or pump activation) can be synchronized with the activation of the ultrasound implant to enhance local absorption of the drug at the target organ, and the implant would then be located near an artery supplying the target organ. For example, chemotherapy flow into a solid tumor could be enhanced during a chemotherapy course.

[0479] Although certain embodiments have been shown and described herein, it will be appreciated by those of ordinary skill in the art that various alternative or equivalent embodiments or implementations intended to achieve the same or similar purposes may replace the illustrated embodiments and are described herein without departing from the scope of the invention. It will be readily appreciated by those skilled in the art that embodiments according to the invention may be implemented in a variety of ways. The present application is intended to cover any and all modifications and / or variations of the embodiments discussed herein.

[0480] The terms and expressions used in the foregoing description are used therein as terms of description rather than limitation, and there is no intention in the use of such terms and expressions to exclude equivalents of the features shown and / or described, or portions thereof, it being recognized that the scope of the present invention is defined and limited solely by the appended claims.

[0481] It will be apparent to those skilled in the art that, according to the above teachings of the present disclosure, multiple modifications and variations of the described examples and embodiments are possible. The disclosed examples and embodiments are presented for illustrative purposes only. Other alternative embodiments may include some or all of the features disclosed herein. Therefore, it is intended to cover all such modifications and alternative embodiments that may fall within the true scope of the present invention, and the present invention will be given its full breadth. In addition, the disclosure of a numerical range is the disclosure of each numerical value within the range.

Claims

1. A device adapted to be implanted in the vicinity of at least one blood vessel or tissue containing flowing blood, the device comprising at least one ultrasonic transducer configured to provide ultrasonic energy to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is adapted to induce a physiological effect in the at least one blood vessel or tissue when applied; the device communicating with at least one on-skin remote control located outside the patient's body, the at least one on-skin remote control adapted to control the ultrasonic energy; Wherein the device is in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

2. The device according to claim 1, wherein: The device is automatically activated when the at least one physiological state changes.

3. The device according to claim 1, wherein: The patient activates the ultrasound energy or modifies the at least one treatment parameter when the at least one physiological state changes.

4. The device of any one of claims 1 to 3, suitable for treating pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma patients, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

5. The device according to claim 1, wherein the sensor is selected from the group consisting of: accelerometer, impedance measurement, photoplethysmography, PPG sensor, pH sensor, ultrasonic sensor, echocardiogram, ultrasonic echo, hydrophone, thermometer, core body temperature, heart pulse rate, pulse wave characteristics, glucose sensor, any sensor indicating changes in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, acoustic blood pulse wave sensor, electrocardiogram sensor, ultrasound sensor or vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein the sensor is suitable for sensing at least one parameter selected from the group consisting of: movement of the patient, impedance, PPG signal, pH, acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

6. The device according to any one of claims 1 to 5, wherein the ultrasound transducer is a transducer array.

7. The device of claim 6, wherein the position and orientation of each of the transducers is controllable.

8. The device of claim 6, wherein the ultrasound transducer array facilitates directing a focused ultrasound beam to the at least one blood vessel or tissue containing flowing blood.

9. The device of claim 6, wherein the ultrasound transducer array facilitates beam steering of the ultrasound energy.

10. The device of claim 6, wherein the ultrasound transducer array facilitates directing of ultrasound energy onto the at least one vessel or tissue containing flowing blood.

11. The apparatus of claim 6, wherein the array generates the ultrasonic energy having at least one ultrasonic carrier frequency.

12. The device according to claim 1, wherein at least one selected from the group consisting of the at least one on-skin remote control, the device, and any combination thereof comprises at least one coil for forming an inductive link and transmitting the ultrasonic energy from the at least one on-skin remote control transcutaneously to the at least one ultrasonic transducer.

13. The device according to any one of claims 1 to 12, wherein the at least one on-skin remote control is adapted to drive the device by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

14. A device according to any one of claims 1 to 13, wherein the at least one on-skin remote control is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) adjusting the treatment provided to the patient; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof. The device according to claim 14 , wherein the data is the shape of a pulse wave signal.

16. The device of claim 14, wherein the data is a time delay between an ECG signal and a pulse wave signal.

17. The device according to any one of claims 1 to 16, wherein the device is encapsulated in at least one layer of polyetheretherketone (PEEK), wherein the radiation surface of the PEEK is an acoustic matching layer; further, wherein the radiation surface of the PEEK has a quarter λ, wherein λ is the wavelength of ultrasonic energy in the PEEK.

18. The device of claim 17, wherein the implant envelope is coated with parylene.

19. The device of claim 1, wherein the at least one transducer is a piezoelectric transducer made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, a composite material, PZT with non-uniform polarization, PZT with uniform polarization, and any combination thereof.

20. A device according to any one of claims 1 to 19, wherein the ultrasonic energy can be provided in a continuous manner or alternatively in pulses.

21. The apparatus of claim 20, wherein the at least one on-skin remote control is adapted to measure heart rate from the at least two pulse wave pulses.

22. The device of claim 21, wherein analysis of the at least two pulse wave characteristics facilitates alignment of the implant relative to the location of the at least one blood vessel or tissue containing flowing blood.

23. The device of claim 20, wherein at least one of the following is true: (a) the ultrasonic frequency is between 10 kHz and 10 MHz; (b) the ultrasonic energy has a peak negative pressure between about 0.1 MPa and about 2 MPa; and any combination thereof.

24. The device of claim 20, wherein the ultrasonic energy is synchronized with the pulse wave signal.

25. The device according to any one of claims 1 to 24, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, application of at least one medical treatment to the patient, a change in application of at least one medical treatment to the patient, and any combination thereof.

26. The device according to claim 1, wherein When the at least one physiological state changes, at least one notification is sent to the patient or any caregiver thereof.

27. The device of claim 1, wherein the physiological effect is selected from the group consisting of: vasodilation, increase in local ATP, enhanced ATP release, increase in local nitric oxide, enhanced nitric oxide release from vascular endothelium; prolonged local nitric oxide effect; enhanced nitric oxide release from red blood cells; altered red blood cell function; altered oxygen release from hemoglobin, increased blood temperature; vasodilation; Prolonging the local nitric oxide effect; Alteration of red blood cell function; alteration of oxygen release from hemoglobin; alteration of blood pH; modulation of immune response of blood leukocytes; modulation of coagulation and / or platelet function; alteration of function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis treatments, arterial dilation, increased blood perfusion, and combinations thereof.

28. A device according to any one of claims 1 to 27, wherein at least one of the at least one on-skin remote controls is wearable by the patient; further, wherein the at least one on-skin remote control wearable by the patient is selected from the group consisting of: integrated in wearable socks, shoes, gloves, clothes, hats, and any combination thereof.

29. The device of claim 4, wherein the ischemic tissue is selected from the group consisting of upper and lower extremities, arms, legs, and any combination thereof.

30. The device according to any one of claims 1 to 29, wherein the at least one on-skin remote control is suitable for controlling at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of the ultrasonic energy.

31. The device of claim 30, wherein the at least one on-skin remote control is in communication with the at least one sensor.

32. The device of any one of claims 1 to 31, wherein when at least one of the physiological states of the patient changes, at least one of the following is performed: (a) activating the device and delivering ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (b) modifying at least one treatment parameter of the ultrasonic energy to the at least one vessel or tissue to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

33. A device according to any one of claims 1 to 32, wherein the sensor is selected from the group consisting of: a sensor implanted in the patient's body integrated within the device, a sensor worn by the patient, a remote sensor outside the patient's body integrated within at least one on-skin remote control, and any combination thereof.

34. The device according to any one of claims 1 to 33, wherein the at least one ultrasound transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by the at least one blood vessel or tissue containing flowing blood.

35. The device according to any one of claims 1 to 34, wherein the device is implanted subcutaneously.

36. A device suitable for implantation near at least one blood vessel or tissue containing flowing blood, the device comprising at least one pulse wave sensor, the at least one pulse wave sensor being suitable for sensing at least one sound wave generated by the at least one blood vessel or tissue containing flowing blood, and thereby monitoring at least one physiological state of the patient.

37. The device according to claim 36, wherein the at least one pulse wave sensor is at least one transducer; further, wherein the transducer is selected from the group consisting of: a capacitive element, an accelerometer, a piezoelectric element, an electromagnetic acoustic element, an electrostatic element, and any combination thereof.

38. The device of claim 36, wherein the device communicates with or otherwise comprises at least one sensor selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, an echocardiogram, an ultrasonic echo, a hydrophone, a thermometer, core body temperature, heart pulse rate, pulse wave characteristics, a glucose sensor, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, an electrocardiogram sensor, an ultrasound sensor or a vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein the sensor is adapted to sense at least one parameter selected from the group consisting of: movement of the patient, impedance, a PPG signal, pH, an acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

39. The device of claim 37, wherein the ultrasound transducer is a transducer array.

40. The device of any one of claims 36 to 39, wherein the device is encapsulated in at least one layer of polyetheretherketone (PEEK), wherein the radiating surface of the PEEK is an acoustic matching layer.

41. The device of claim 40, wherein the implant envelope is coated with parylene.

42. The device of claim 37, wherein the at least one transducer is a piezoelectric transducer made of at least one material selected from the group consisting of lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, a composite material, PZT with non-uniform polarization, PZT with uniform polarization, and any combination thereof.

43. An apparatus according to claim 36, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, application of at least one medical treatment to the patient, a change in application of at least one medical treatment to the patient, and any combination thereof.

44. The apparatus of claim 36, wherein: When the at least one physiological state changes, at least one notification is sent to the patient or any caregiver thereof.

45. The device according to any one of claims 36 to 44, wherein the device is implanted subcutaneously.

46. ​​An implant adjacent to or within at least one blood vessel or tissue containing flowing blood, the implant comprising: i. at least one housing comprising at least one coil for forming an inductive link and transmitting the ultrasonic energy transcutaneously from at least one on-skin remote control to at least one ultrasonic transducer; as well as ii. at least one sealed pigtail connected by wire or wirelessly to the at least one housing comprising the at least one ultrasonic transducer, the at least one ultrasonic transducer being configured to couple ultrasonic energy to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is suitable for causing a physiological effect in the at least one blood vessel or tissue when applied; The housing is in communication with the at least one on-skin remote control located external to the patient, the at least one on-skin remote control being adapted to control the ultrasound energy.

47. The implant of claim 46, wherein at least one selected from the group consisting of the at least one housing, the at least one sealing pigtail, and any combination thereof, communicates with at least one sensor adapted to monitor at least one physiological condition of the patient.

48. The implant of claim 47, wherein The implant is automatically activated when the at least one physiological state changes.

49. The implant of claim 47, wherein The patient activates the ultrasound energy or modifies the at least one treatment parameter when the at least one physiological state changes.

50. An implant according to any one of claims 47 to 49 suitable for treating pulmonary artery denervation, pulmonary hypertension, ischemic tissue, PAD, CLI, pulmonary hypertension, severe asthma patients, improving blood flow to the brain during stroke, increasing blood flow to the penis to maintain erection, enhancing the bioavailability of drugs, enhancing local chemotherapy absorption into solid tumors by enhancing flow to specific arteries supplying the tumor, and any combination thereof.

51. The implant of claim 47, wherein the sensor is selected from the group consisting of: an accelerometer, an impedance measurement, a photoplethysmography, a PPG sensor, a pH sensor, an ultrasonic sensor, an echocardiogram, an ultrasonic echo, a hydrophone, a thermometer, a core body temperature, a heart pulse rate, a pulse wave characteristic, a glucose sensor, any sensor indicating a change in cardiac output, any sensor indicating blood pressure, any sensor indicating the start of a dialysis session, an acoustic blood pulse wave sensor, an electrocardiogram sensor, an ultrasound sensor or a vibration sensor, any sensor associated with a dialysis machine, and any combination thereof; further, wherein the sensor is suitable for sensing at least one parameter selected from the group consisting of: the patient's movement, impedance, a PPG signal, pH, an acoustic signal, pressure, temperature, heart rate, pulse wave characteristics, glucose level, blood pressure, and any combination thereof.

52. An implant according to any one of claims 46 to 51, wherein the ultrasound transducer is a transducer array.

53. The implant of claim 52, wherein the array generates the ultrasonic energy having at least one ultrasonic carrier frequency.

54. The implant of claim 46, wherein the at least one on-skin remote control comprises at least one coil for forming an inductive link and transcutaneously transmitting the ultrasonic energy from the at least one on-skin remote control to the at least one ultrasonic transducer.

55. The implant according to any one of claims 46 to 54, wherein the at least one on-skin remote control is adapted to drive the implant by at least one method selected from the group consisting of electromagnetic, ultrasonic, capacitive, inductive, and any combination thereof.

56. An implant according to any one of claims 46 to 55, wherein the at least one on-skin remote control is suitable for collecting data from the at least one sensor and performing at least one item selected from the group consisting of: (a) monitoring the data; (b) adjusting the treatment provided to the patient; (c) maintaining the treatment provided to the patient unchanged; and any combination thereof.

57. An implant according to claim 56, wherein the data is the shape of the pulse wave signal.

58. The implant of claim 56, wherein the data is a time delay between an ECG signal and a pulse wave signal.

59. The implant of any one of claims 46 to 58, wherein the implant is implanted subcutaneously.

60. The implant of claim 59, wherein the implant envelope is coated with parylene.

61. An implant according to claim 46, wherein the at least one transducer is a piezoelectric transducer made of at least one material selected from the group consisting of: lead zirconate titanate, lead magnesium niobate-titanate, hard PZT, a composite material, PZT with non-uniform polarization, PZT with uniform polarization, and any combination thereof.

62. An implant according to any one of claims 46 to 61, wherein the ultrasonic energy can be provided in a continuous manner or alternatively in pulses.

63. The implant of claim 62, wherein the at least one on-skin remote control is adapted to measure heart rate from the at least two pulse wave pulses.

64. The implant of claim 63, wherein analysis of the at least two pulse wave characteristics facilitates alignment of the implant relative to the position of the at least one blood vessel or tissue containing flowing blood.

65. The implant of claim 62, wherein at least one of the following is true: (a) the ultrasonic frequency is between 10 kHz and 10 MHz; (b) the ultrasonic energy has a peak negative pressure between about 0.1 MPa and about 2 MPa; and any combination thereof.

66. The implant of claim 62, wherein the ultrasonic energy is synchronized with the pulse wave signal.

67. An implant according to any one of claims 46 to 66, wherein the physiological state or change thereof is selected from the group consisting of: the position of the patient, participation in physical activity, a decrease in NO levels in at least one vessel or tissue, tissue perfusion, the onset of physical activity, a change in at least one parameter associated with the physical activity, the position of the patient relative to the ground, a change in the position of the patient relative to the ground, application of at least one medical treatment to the patient, a change in the application of at least one medical treatment to the patient, and any combination thereof.

68. The implant of claim 46, wherein When the at least one physiological state changes, at least one notification is sent to the patient or any caregiver thereof.

69. The implant of claim 46, wherein the physiological effect is selected from the group consisting of: vasodilation, increase in local ATP, enhanced ATP release, increase in local nitric oxide, enhanced nitric oxide release from vascular endothelium; prolonged local nitric oxide effect; enhanced nitric oxide release from red blood cells; altered red blood cell function; altered oxygen release from hemoglobin, increased blood temperature; vasodilation; Prolonging the local nitric oxide effect; Alteration of red blood cell function; alteration of oxygen release from hemoglobin; alteration of blood pH; modulation of immune response of blood leukocytes; modulation of coagulation and / or platelet function; alteration of function of heme-catalyzed enzymes in the blood, improved bioavailability of drugs, improved efficacy of hemodialysis treatments, arterial dilation, increased blood perfusion, and combinations thereof.

70. An implant according to any one of claims 46 to 69, wherein at least one of the at least one on-skin remote controls is wearable by the patient; further, wherein the at least one on-skin remote control wearable by the patient is selected from the group consisting of: integrated into wearable socks, shoes, gloves, clothing, hats, and any combination thereof.

71. The implant of claim 50, wherein the ischemic tissue is selected from the group consisting of upper and lower extremities, arms, legs, and any combination thereof.

72. An implant according to any one of claims 46 to 71, wherein the at least one on-skin remote control is suitable for controlling at least one parameter selected from the group consisting of: phase, operating frequency, power, intensity, operating amplitude, timing, duration, and any combination thereof of the ultrasonic energy.

73. The implant of claim 72, wherein the at least one on-skin remote control communicates with the at least one sensor.

74. An implant according to any one of claims 46 to 73, wherein when at least one of the physiological states of the patient changes, at least one of the following is performed: (a) delivering ultrasonic energy to the at least one blood vessel or tissue to provide on-demand treatment; (b) modifying at least one treatment parameter provided by the ultrasonic energy to the at least one blood vessel or tissue to provide on-demand treatment; (c) notifying the change; (d) any combination thereof.

75. An implant according to any one of claims 46 to 74, wherein the sensor is selected from the group consisting of: a sensor integrated in the at least one housing, integrated in the at least one pigtail and implanted in the patient's body, a sensor worn by the patient, a remote sensor outside the patient's body integrated in the at least one on-skin remote control, and any combination thereof.

76. An implant according to any one of claims 46 to 75, wherein the at least one ultrasound transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by the at least one blood vessel or tissue containing flowing blood.

77. The implant of claim 46, wherein the at least one ultrasonic transducer acts as an acoustic sensor and is adapted to sense at least one sound wave generated by the at least one blood vessel or tissue containing flowing blood.

78. A method of treating a patient, the method comprising the steps of: a. providing at least one device adapted to be implanted in a patient's body near at least one blood vessel or tissue containing flowing blood, the at least one device comprising at least one ultrasonic transducer, the at least one ultrasonic transducer being configured to provide ultrasonic energy to be applied to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is adapted to induce a physiological effect in the at least one blood vessel or tissue when applied; b. communicating said device with at least one on-skin remote controller located outside the patient's body, said at least one on-skin remote controller being adapted to control said means for applying said ultrasonic energy; c. implanting the at least one device near at least one blood vessel or tissue containing flowing blood; as well as d. Placing the device in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

79. A method of treating a patient, the method comprising the steps of: a. providing at least one implant near or within at least one blood vessel or tissue containing flowing blood, the at least one implant comprising (i) at least one housing comprising at least one coil for forming an inductive link and transmitting the ultrasonic energy from at least one on-skin remote control transcutaneously to at least one ultrasonic transducer; (ii) at least one sealed pigtail connected by wire or wireless connection to the at least one housing including the at least one ultrasonic transducer, the at least one ultrasonic transducer being configured to couple ultrasonic energy to the at least one blood vessel or tissue containing flowing blood, wherein the ultrasonic energy is suitable for inducing a physiological effect in the at least one blood vessel or tissue when applied; b. communicating said implant with at least one on-skin remote controller located outside the patient's body, said at least one on-skin remote controller being adapted to control said device for applying said ultrasonic energy; c. implanting the at least one implant near or within at least one blood vessel or tissue containing flowing blood; as well as d. Placing the implant in communication with at least one sensor adapted to monitor at least one physiological state of the patient.

80. A method of monitoring at least one physiological state of a patient, the method comprising the steps of: a. providing at least one implant near at least one blood vessel or tissue containing flowing blood, the at least one implant comprising at least one pulse wave sensor adapted to sense at least one acoustic wave generated by the at least one blood vessel or tissue containing flowing blood, and thereby monitoring the at least one physiological state of the patient; b. implanting the at least one implant near at least one blood vessel or tissue containing flowing blood; and c. sensing at least one acoustic wave generated by the at least one blood vessel or tissue containing flowing blood to thereby monitor at least one physiological state of the patient.

Citation Information

Patent Citations

  • Extracorporeal therapeutic ultrasound for promoting angiogenesis

    WO2018071908A1